-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 TMiO/SZe1VUDybgoCfbPkx+FZnpvyL9CAsHrTXfEgvvxdinjlOPMrj569sZyUVhW
 QqJsLDfNLOycWQewgUElpQ==

<SEC-DOCUMENT>0000109657-06-000080.txt : 20061113
<SEC-HEADER>0000109657-06-000080.hdr.sgml : 20061113
<ACCEPTANCE-DATETIME>20061113152719
ACCESSION NUMBER:		0000109657-06-000080
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20061106
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20061113
DATE AS OF CHANGE:		20061113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OXIS INTERNATIONAL INC
		CENTRAL INDEX KEY:			0000109657
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				941620407
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-08092
		FILM NUMBER:		061208629

	BUSINESS ADDRESS:	
		STREET 1:		323 VINTAGE PARK DRIVE, SUITE B
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		6502122568

	MAIL ADDRESS:	
		STREET 1:		323 VINTAGE PARK DRIVE, SUITE B
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DDI PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DIAGNOSTIC DATA INC /DE/
		DATE OF NAME CHANGE:	19850312
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>oxisform8k.htm
<DESCRIPTION>OXIS FORM 8-K 11-13-06
<TEXT>
<html>
  <head>
    <title>
      OXIS Form 8-K 11-13-06
</title>
<!-- Licensed to: OXIS International, Inc.-->
<!-- Document Created using EDGARizer HTML 3.0.4.0 -->
<!-- Copyright 2006 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>UNITED
      STATES </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington
      D.C., 20549 </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>Form
      8-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>Current
      Report</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">Pursuant
      to Section 13 or 15(d) of the Securities Exchange Act of 1934 </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date
      Of
      Report (Date Of Earliest Event Reported):</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
      11/6/2006</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><img src="oxislogo.jpg" alt=""></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Exact
      Name of Registrant as Specified in its Charter)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
      File Number:</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;&#160;0-8092</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="bottom" width="49%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>DE</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
            </td>
            <td align="left" valign="bottom" width="3%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
            </td>
            <td valign="bottom" width="32%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>94-1620407</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="49%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(State
                or Other Jurisdiction of</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
            </td>
            <td align="left" valign="bottom" width="3%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
            </td>
            <td valign="bottom" width="32%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(I.R.S.
                Employer</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="49%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incorporation
                or Organization)</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
            </td>
            <td align="left" valign="bottom" width="3%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
            </td>
            <td valign="bottom" width="32%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Identification
                No.)</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>323
      Vintage Park Drive, Suite B, Foster City, California 94404</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of Principal Executive Offices, Including Zip Code)</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>650-212-2568</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Registrant&#8217;s
      Telephone Number, Including Area Code) </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Former
      name or former address, if changed since last report) </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Check
      the
      appropriate box below if the Form 8-K filing is intended to simultaneously
      satisfy the filing obligation of the registrant under any of the following
      provisions:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">[&#160;&#160;]&#160;&#160;
      Written communications pursuant to Rule 425 under the Securities Act (17 CFR
      230.425)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">[&#160;&#160;]&#160;&#160;
      Soliciting material pursuant to Rule 14a-12 under the Exchange
      Act(17CFR240.14a-12)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">[&#160;&#160;]&#160;&#160;
      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
      Act(17CFR240.14d-2(b))</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">[&#160;&#160;]&#160;&#160;
      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
      Act(17CFR240.13e-4(c)) </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Item
        1.01.</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 49.5pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Entry
        into a Material Definitive Agreement.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
        November 6, 2006, OXIS International, Inc. (&#8220;OXIS&#8221;) entered into an Employment
        Agreement with Marvin S. Hausman, M.D., the President and Chief Executive
        Officer of OXIS and the Chairman of the Board of Directors. The commencement
        date of the agreement was set retroactively at October 15, 2006 (the
&#8220;Commencement Date&#8221;).</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
        to the Employment Agreement, Dr. Hausman will continue to serve as the President
        and Chief Executive Officer of OXIS for a three year period from the
        Commencement Date, thereafter on a one year basis. Dr. Hausman will receive
        annual compensation in the amount of $250,000, payable quarterly in advance
        in
        cash, common stock based on a price equal to 85% of average of the five closing
        prices for the five trading days prior to the date that the issuance is
        authorized by the Board of Directors, or in ten year warrants equal to that
        number of warrants equal to 1.5 times the number of shares that would otherwise
        be received. For the initial quarterly payment, Dr. Hausman was issued 347,222
        restricted shares. During the three year term of the agreement, Dr. Hausman
        shall receive an annual bonus based upon the attainment of agreed upon goals
        and
        milestones as determined by the Board of Directors and its Compensation
        Committee. During the remainder of calendar year 2006, Dr. Hausman&#8217;s bonus shall
        be pro rated on an annual bonus rate in the range of 25% to 50% of his base
        salary, and the bonus for subsequent years of the term of the agreement shall
        be
        in a similar target range. The bonuses payable hereunder shall be paid in
        cash,
        although at Dr. Hausman&#8217;s sole option, they may be paid in stock (or in the form
        of ten year warrants with cashless exercise provisions, with 1.5 times the
        number of warrants to be issued in lieu of the number of shares of common
        stock), based upon the average of the closing bid and asked prices for the
        5
        trading days immediately prior to the awarding to Dr. Hausman of the bonus
        for a
        particular year. Once OXIS has raised at least $2.5 million in one or more
        financings (equity, debt or convertible debt, in addition to the financing
        closed on October 25, 2006) or in a strategic transaction (in each case,
        a
        Qualifying Finance), Dr. Hausman may elect, at any time, in lieu of receiving
        a
        quarterly issuance of stock (or warrants in lieu thereof), to receive his
        base
        salary in cash, payable monthly on OXIS&#8217;s regular pay cycle for professional
        employees. As part of the compensation under the Employment Agreement, OXIS
        granted Dr. Hausman a ten year a non-qualified option to purchase 495,000
        shares
        of OXIS common stock at an exercise price of $0.20 per share, vesting as
        follows: (i) 247,500 options vesting in four equal quarterly installments
        commencing on January 15, 2007 and every three months thereafter and (ii)
        and
        the remaining 247,500 options vesting in eight quarterly installments over
        the
        following two years (the &#8220;Initial Option Grant&#8221;). Additionally, OXIS granted Dr.
        Hausman, as a sign on bonus, 500,000 restricted shares of common stock and
        a ten
        year common stock purchase warrant to purchase 1,505,000 shares at an exercise
        price of $0.20 per share, with vesting in six equal installments, commencing
        on
        November 14, 2006, through the 180</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>th</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        day
        after the Commencement Date. OXIS shall provide Dr. Hausman with an annual
        office expense allowance of $50,000, for the costs of maintaining an office
        in
        the Stevenson, Washington area. The office expense allowance shall be payable
        quarterly in advance in the form of common stock, at a price equal to 85%
        of the
        Market Price. For the first installment, representing $12,500 of the office
        expense allowance, Dr. Hausman was issued 69,444 restricted shares of common
        stock. Hereafter, the office allowance expense will be paid promptly after
        the
        determination of the Market Price on the dates that are three months, six
        months
        and nine months from the date hereof, and quarterly thereafter for the duration
        of the term of the agreement. Notwithstanding the foregoing, once OXIS has
        completed a Qualifying Financing, the office expense allowance will be paid
        in
        cash in advance, commencing for the quarter next following the quarter in
        which
        the Qualifying Financing occurred. Additionally, Dr. Hausman shall receive
        family health and dental insurance benefits and short-term and long-term
        disability policies.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div><br>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">1</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Upon
        termination for cause, all compensation due to Dr. Hausman under the agreement
        will cease, other than a right to participate in continued group health
        insurance for a certain period of time (this applies to all terminations,
        except
        if Dr, Hausman terminates without good reason) and any unexercised portions
        of
        his stock options shall expire upon such termination. In the event that OXIS
        terminates Dr. Hausman&#8217;s employment within one year of a change of control, Dr
        Hausman shall receive an amount equal to twelve months of base salary for
        the
        then current term of the agreement (which is in addition to the base salary
        paid
        to Dr. Hausman after OXIS&#8217; delivery of notice of termination and the actual date
        of termination) plus an amount equal to the prior year&#8217;s bonus (and if occurring
        before the bonus for 2007 has been determined, an amount equal to 50% of
        the
        then current base salary), and the full vesting of Dr. Hausman&#8217;s stock options,
        and extended exercisability thereof until their respective expiration dates.
        In
        the event that the OXIS terminates its relationship with Dr. Hausman, including
        a non-renewal of the agreement by OXIS, but other than upon a change of control,
        death, disability or cause, Dr. Hausman shall receive the following: (i)
        if
        employment was terminated during the calendar year 2006, an amount equal
        to six
        months of the then current base salary; if employment was terminated commencing
        in the calendar year 2007 or if OXIS elects not to renew the agreement, an
        amount equal to twelve months of base salary for the then current term of
        the
        agreement plus an amount equal to the prior year&#8217;s bonus (and if occurring
        before the bonus for 2007 has been determined, an amount equal to 50% of
        the
        then current base salary); (ii) if employment was terminated during the calendar
        year 2006, 50% of the previously unvested portion of the Initial Option Grant
        shall vest and such vested options shall be exercisable until their respective
        expiration dates; if employment was terminated commencing in the calendar
        year
        2007 and thereafter or if OXIS elects not to renew the agreement following
        the
        initial three year term or any additional term, all stock options granted
        to Dr.
        Hausman (including without limitation the Initial Option Grant) shall
        immediately vest and shall remain exercisable until their respective expiration
        dates. In the event Dr. Hausman terminates his relationship with OXIS for
        good
        reason within one (1) year of the occurrence of the event which established
        the
        good reason, or for good reason within one year of a change of control, Dr.
        Hausman shall receive the following: (i) if the termination occurred during
        the
        calendar year 2006 for good reason, an amount equal to six months of base
        salary; if the termination occurred during the calendar year 2006 due to
        a
        change of control, an amount equal to twelve months of base salary; if
        termination for good reason occurred during the calendar year 2007 or
        thereafter, an amount equal to twelve months of the then current base salary
        plus an amount equal to the prior year&#8217;s bonus (and if occurring before the
        bonus for 2007 has been determined, an amount equal to 50% of the then current
        base salary); (ii) if termination occurred during the calendar year 2006,
        50% of
        the previously unvested portion of the Initial Option Grant shall vest and
        such
        vested options shall be exercisable until their respective expiration dates,
        except that if termination is by Dr. Hausman for good reason subsequent to
        a
        change of control, then 100% of any option grants to Dr. Hausman (including,
        without limitation, the Initial Option Grant) shall vest and shall remain
        exercisable until its respective expiration dates; if employment was terminated
        commencing in the calendar year 2007 and thereafter, all stock options granted
        to Dr. Hausman (including, without limitation, the Initial Option Grant)
        shall
        immediately vest and shall remain exercisable until their respective expiration
        dates.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div><br>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">2</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
        November 6, 2006, OXIS entered into an Advisory Agreement with Ambient Advisors
        LLC (the &#8220;Advisor&#8221;). Gary M. Post, a member of the board of directors, is the
        manager of Ambient Advisors LLC. The commencement date of the agreement was
        set
        retroactively at October 15, 2006 (the &#8220;Commencement Date&#8221;).</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
        to the Advisory Agreement, the Advisor will provide certain services pertaining
        to strategic planning, financial planning and budgeting, investor relations,
        corporate finance and such additional roles and responsibilities as requested
        for a three year period from the Commencement Date, thereafter on a one year
        basis. The Advisor will receive annual compensation in the amount of $83,333,
        payable quarterly in advance in cash, common stock based on a price equal
        to 85%
        of average of the five closing prices for the five trading days prior to
        the
        date that the issuance is authorized by the Board of Directors, or in ten
        year
        warrants equal to that number of warrants equal to 1.5 times the number of
        shares that would otherwise be received. For the initial quarterly payment,
        the
        Advisor received a ten year warrant to purchase 173,608 shares with an exercise
        price of $0.20 per share, vesting immediately. As part of the compensation
        under
        the Advisory Agreement, OXIS granted the Advisor a ten year common stock
        purchase warrant to purchase 550,000 shares of OXIS common stock at an exercise
        price of $0.20 per share, vesting as follows: (i) 275,000 warrants vesting
        in
        four equal quarterly installments commencing on January 15, 2007 and every
        three
        months thereafter and (ii) and the remaining 275,000 warrants vesting in
        eight
        quarterly installments over the following two years. Additionally, OXIS granted
        the Advisor, as a sign on bonus, a non-qualified option to purchase 333,333
        shares at exercise price of $0.20 per share, with vesting in six equal
        installments, commencing on November 14, 2006, through the 180</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>th</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        day
        after the Commencement Date. During the three year term of the agreement,
        the
        Advisor shall receive an annual bonus based upon the attainment of agreed
        upon
        goals and milestones as determined by the Board of Directors and its
        Compensation Committee. During the remainder of calendar year 2006, the
        Advisor&#8217;s bonus shall be pro rated on an annual bonus rate in the range of 25%
        to 50% of the advisory fee, and the bonus for subsequent years of the term
        of
        the agreement shall be in a similar target range. The bonuses payable hereunder
        shall be paid in cash, although at the Advisor&#8217;s sole option, they may be paid
        in stock (or in the form of ten year warrants with cashless exercise provisions,
        with 1.5 times the number of warrants to be issued in lieu of the number
        of
        shares of common stock), based upon the average of the closing bid and asked
        prices for the 5 trading days immediately prior to the awarding to the Advisor
        of the bonus for a particular year.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
        OXIS
        terminates the Advisory Agreement without cause after the six month anniversary
        of November 6, 2006, the Advisor shall receive an amount equal to twelve
        months
        of the advisory fee in a lump sum payment and all outstanding stock options
        shall become fully vested and </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
        warrants vested as of the date of termination and the stock options </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">shall
        remain exercisable through their respective expiration dates. If OXIS terminates
        this Agreement without cause prior the six month anniversary of November
        6,
        2006, Advisor shall be paid any expenses due to him and all vested stock
        options
        and warrants shall remain exercisable through their respective expiration
        dates.
        If OXIS terminates Advisor for cause, Advisor shall not be entitled to any
        further payments of its advisory fee hereunder, and any unexercised stock
        options shall expire. If the Advisor resigns for whatever reason, or if Gary
        M.
        Post dies or becomes disabled, the Advisor shall not be entitled to any further
        payments of the advisory fee hereunder, all unvested stock options and warrants
        shall expire, and all vested stock options and warrants shall remain exercisable
        until their respective expiration dates.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div><br>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">3</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
        November 6, 2006, OXIS entered into an Consulting Agreement with John E.
        Repine,
        M.D. The commencement date of the agreement was set retroactively at October
        15,
        2006 (the &#8220;Commencement Date&#8221;).</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
        to the Consulting Agreement, Dr. Repine shall advise OXIS concerning matters
        of
        antioxidant and inflammation research and potential acquisitions (including
        products/compounds/intellectual property, companies), product research and
        development, and the development and establishment of reference labs for
        oxidative stress and inflammatory reactions for a three year period from
        the
        Commencement Date, thereafter on a one year basis. Dr. Repine will receive
        annual compensation in the amount of $36,000, payable quarterly in advance
        in
        cash, common stock based on a price equal to 85% of average of the five closing
        prices for the five trading days prior to the date that the issuance is
        authorized by the Board of Directors, or in ten year warrants equal to that
        number of warrants equal to 1.5 times the number of shares that would otherwise
        be received. For the initial quarterly payment, Dr. Repine received 50,000
        restricted shares. As part of the compensation under the Consulting Agreement,
        OXIS granted Dr. Repine a ten year stock option to purchase 200,000 shares
        of
        OXIS common stock at an exercise price of $0.20 per share, vesting as follows:
        (i) 100,000 options vesting in four equal quarterly installments commencing
        on
        January 15, 2007 and every three months thereafter and (ii) and the remaining
        100,000 options vesting in eight quarterly installments over the following
        two
        years. Additionally, OXIS granted Dr. Repine, as a sign on bonus, a
        non-qualified option to purchase 200,000 shares at exercise price of $0.20
        per
        share, with vesting in six equal installments, commencing on November 14,
        2006,
        through the 180</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>th</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        day
        after the Commencement Date. During the term of the Consulting Agreement,
        Dr.
        Repine shall be eligible to receive annual and special bonuses based upon
        the
        attainment of agreed upon goals and milestones as determined by the OXIS
        Chief
        Executive Officer. Each bonus payable shall be paid in cash, although at
        Dr.
        Repine&#8217;s sole option, such bonus may be paid in stock (or in the form of ten
        year warrants with cashless exercise provisions, with 1.5 times the number
        of
        warrants to be issued in lieu of the number of shares of common stock), based
        upon the average of the closing bid and asked prices for the 5 trading days
        immediately prior to the awarding to Dr. Repine of the particular bonus.
        </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
        OXIS
        terminates the Consulting Agreement without cause after the six month
        anniversary of November 6, 2006, Dr. Repine shall receive an amount equal
        to
        twelve months of the advisory fee in a lump sum payment and all outstanding
        stock options shall become fully vested and </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
        warrants vested as of the date of termination and the stock options </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">shall
        remain exercisable through their respective expiration dates. If OXIS terminates
        this Agreement without cause prior the six month anniversary of November
        6,
        2006, Dr. Repine shall be paid any expenses due to him and all vested stock
        options and warrants shall remain exercisable through their respective
        expiration dates. If OXIS terminates Dr. Repine for cause, Dr. Repine shall
        not
        be entitled to any further payments of his advisory fee hereunder, and any
        unexercised stock options shall expire. If Dr. Repine resigns for whatever
        reason, or if he dies or becomes disabled, Dr. Repine shall not be entitled
        to
        any further payments of the consulting fee hereunder, all unvested stock
        options
        and warrants shall expire, and all vested stock options and warrants shall
        remain exercisable until their respective expiration dates.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All
        shares of common stock issuable to Drs. Hausman, Repine and Ambient Advisors
        or
        issuable upon the exercise of the warrants to be issued in lieu thereof pursuant
        to the above agreements, shall have the benefit of piggyback registration
        rights, pursuant to a Registration Rights Agreement to be executed by OXIS
        and
        Drs. Hausman, Repine and Ambient Advisors.</font></div><br>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">4</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        foregoing summary of the material terms of the Employment Agreement with
        Dr.
        Hausman, the Advisory Agreement with Ambient Advisors and the Consulting
        Agreement with Dr. Repine are qualified in their entirety by the text of
        those
        documents attached as Exhibits 10.1, 10.2, and 10.3 to this Current Report
        on
        Form 8-K and incorporated herein by reference. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Item
        9.01.</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Financial
        Statements and Exhibits.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)
        Exhibits</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td style="width: 36pt;">&#160;</td>
              <td style="width: 36pt;">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.1</font></div>
              </td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Employment
                  Agreement between OXIS International, Inc. and Marvin S. Hausman,
                  M.D.
                  dated November 6, 2006.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td style="width: 36pt;">&#160;</td>
              <td style="width: 36pt;">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.2</font></div>
              </td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Advisory
                  Agreement between OXIS International, Inc. and Ambient Advisors,
                  LLC dated
                  November 6, 2006.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td style="width: 36pt;">&#160;</td>
              <td style="width: 36pt;">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.3</font></div>
              </td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Consulting
                  Agreement between OXIS International, Inc. and John E. Repine,
                  M.D. dated
                  November 6, 2006.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><br>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">5</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Signature(s)
        </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
        to the Requirements of the Securities Exchange Act of 1934, the Registrant
        has
        duly caused this Report to be signed on its behalf by the Undersigned hereunto
        duly authorized. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

              <tr valign="top" bgcolor="#ffffff">
                <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
                <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
                <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
              </tr>
              <tr valign="top" bgcolor="#ffffff">
                <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
                <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: "><strong>OXIS
                  INTERNATIONAL, INC.</strong></font></td>
              </tr>
              <tr valign="top" bgcolor="#ffffff">
                <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
                <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
                <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
              </tr>
              <tr valign="top" bgcolor="#ffffff">
                <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">Date:&#160;
                  November 13, 2006</font></td>
                <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">By:&#160;&#160;</font></td>
                <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">/s/&#160;MICHAEL
                  D. CENTRON</font></td>
              </tr>
              <tr valign="top" bgcolor="#ffffff">
                <td colspan="2"><font style="FONT-FAMILY: " size="1">&#160;</font></td>
                <td align="left">
                  <hr style="COLOR: black" align="left" noshade size="2" width="80%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Michael
                  D. Centron</font></td>
              </tr>
              <tr valign="top" bgcolor="#ffffff">
                <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
                <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">Title:&#160;
Vice
                  President and Chief Financial Officer</font></td>
              </tr>

          </table>
        </div>
        <div>&#160;</div>
        <div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">6</font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
            </font>
            <div>
              <hr style="COLOR: black" align="left" noshade size="2" width="100%">
            </div>
          </div>
        </div>
      </div>
    </div>
  </body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>employmentagreement.htm
<DESCRIPTION>EMPLOYMENT AGREEMENT BETWEEN OXIS INTERNATIONAL, INC. AND MARVIN S. HAUSMAN, M.D. DATED NOVEMBER 6, 2006
<TEXT>
<html>
  <head>
    <title>
      Employment Agreement between OXIS International, Inc. and Marvin S. Hausman,
      M.D. dated November 6, 2006
</title>
<!-- Licensed to: OXIS International, Inc.-->
<!-- Document Created using EDGARizer HTML 3.0.4.0 -->
<!-- Copyright 2006 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Exhibit
      10.1</strong></font></div>
    <div><br>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>EMPLOYMENT
      AGREEMENT</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Employment
      Agreement dated as of</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">November
      6, 2006, between OXIS INTERNATIONAL INC., a Delaware corporation (with its
      successors and assigns, referred to as the &#8220;Corporation&#8221;) and MARVIN S. HAUSMAN,
      M.D. (hereinafter referred to as &#8220;HAUSMAN&#8221;).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PRELIMINARY
      STATEMENT</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Corporation desires to employ HAUSMAN as President and Chief Executive Officer
      of the Corporation, and HAUSMAN wishes to be employed by the Corporation, upon
      the terms and subject to the conditions set forth in this Agreement. The
      Corporation and HAUSMAN also wish to enter into the other agreements set forth
      in this Agreement, all of which are related to HAUSMAN&#8217;s employment under this
      Agreement.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>AGREEMENT</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">HAUSMAN
      and the Corporation therefore agree as follows:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>1</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Term
      of Employment.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      The
      Corporation hereby employs HAUSMAN and HAUSMAN hereby accepts employment with
      the Corporation for the period (the &#8220;Initial Term&#8221;) commencing as of October 15,
      2006 (the &#8220;Commencement Date&#8221;), and ending on the third anniversary of the
      Commencement Date hereof</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">or
      upon
      the earlier termination of the Initial Term pursuant to Section 6. The Initial
      Term will be extended automatically for additional one-year periods (each,
      an
&#8220;Additional Term,&#8221; together with the Initial Term, the &#8220;Term&#8221;), subject to the
      rights of the parties generally to terminate this Agreement in accordance with
      the provisions of Section 6(a). The termination of the Term for any reason
      shall
      end HAUSMAN&#8217;s employment under this Agreement, but, except as otherwise set
      forth herein, shall not terminate HAUSMAN&#8217;s or the Corporation&#8217;s other
      agreements in this Agreement.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Position
      and Duties.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Upon the
      commencement of the Initial Term, HAUSMAN shall serve as President and Chief
      Executive Officer of the Corporation. HAUSMAN shall also serve as the Chairman
      of the Board of Directors and shall also hold such additional positions and
      titles as the Board of Directors (&#8220;Board&#8221;) may determine from time to time.
      HAUSMAN shall report to the Board. During the Term, HAUSMAN shall devote
      substantial time and attention to performing his duties as an employee of the
      Corporation. The Corporation acknowledges that the foregoing sentence shall
      not
      restrict HAUSMAN from devoting time and attention to other business ventures,
      including without limitation those activities identified on Schedule A annexed
      hereto, which the Corporation acknowledges are not business opportunities of
      the
      Corporation. Additionally, HAUSMAN may continue serving on the Board of
      Directors of TorreyPines Therapeutics, Inc. and as a member of its Board
      committees and may serve in similar capacities with other companies or
      organizations subject to his obtaining prior approval from Board. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Compensation.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>a</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>)
      </strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Base
      Salary.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      The
      Corporation shall pay HAUSMAN a base salary, beginning on the first day of
      the
      Initial Term and ending on the last day of the Initial Term, of $250,000 per
      annum. The base salary initially will be payable quarterly in advance in the
      form of the Corporation&#8217;s common stock (&#8220;Common Stock&#8221;), at a price equal to 85%
      of the &#8220;Market Price&#8221; for the Corporation&#8217;s common stock, which shall equal the
      average of the closing price for the five trading days prior to the date that
      the issuance is authorized by the Board of Directors. In lieu of receiving
      Common Stock for such payments, HAUSMAN may elect to receive that number of
      ten
      year Warrants (with cashless exercise provisions) equal to 1.5 times the number
      of shares of Common Stock that would otherwise be received, at an exercise
      price
      equal to the Market Price. The first installment, representing $67,500 of
      HAUSMAN&#8217;s base salary, and payable at HAUSMAN&#8217;s election either in the shares of
      Common Stock or form of warrants described in the foregoing sentence, will
      be
      paid promptly after the initial determination of the Market Price, and
      thereafter, will be paid on the dates that are three months, six months and
      nine
      months from the date hereof, and quarterly thereafter for the duration of the
      Term. Notwithstanding the foregoing, once the Corporation has raised at least
      $2.5 million in one or more financings (equity, debt or convertible debt, in
      addition to the financing closed on October 27, 2006) or in a strategic
      transaction (a &#8220;Qualifying Financing&#8221;), HAUSMAN may elect, at any time, in lieu
      of receiving a quarterly issuance of stock (or warrants in lieu thereof), to
      receive his base salary in cash, payable monthly on the Corporation&#8217;s regular
      pay cycle for professional employees. All shares of Common Stock issuable to
      HAUSMAN under Sections 3 and 4 hereof (if not otherwise registered pursuant
      to
      an existing stock option plan covered by a registration statement on Form S-8),
      or upon the exercise of the warrants to be issued in lieu thereof ,shall have
      the benefit of piggyback registration rights, pursuant to a Registration Rights
      Agreement to be executed by the Corporation and HAUSMAN (the &#8220;Registration
      Rights Agreement&#8221;); provided, however, that the failure to execute such a
      Registration Rights Agreement shall not limit HAUSMAN&#8217;s piggyback registration
      rights hereunder. Furthermore, the Corporation will obtain advice of counsel
      that the issuance of shares of Common Stock by the Corporation to HAUSMAN under
      Sections 3 and 4 hereof do not violate the provisions of Section 203 of the
      Delaware General Corporation Law. Following the Initial Term, the Board shall,
      in accordance with its customary review of executive management compensation,
      review HAUSMAN&#8217;s base salary and make adjustments the Board (or its Compensation
      Committee) feels are appropriate, but in any event HAUSMAN&#8217;s base salary shall
      not be lower than $250,000.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 99pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(b)</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Other
      and Additional Compensation.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(i)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Annual
      Bonus.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      During
      the Term, HAUSMAN shall receive an annual bonus based upon the attainment of
      agreed upon goals and milestones as determined by the Board and its Compensation
      Committee. During the remainder of calendar year 2006, HAUSMAN&#8217;s bonus shall be
      pro rated on an annual bonus rate in the range of 25% to 50% of his base salary,
      and his bonus for subsequent years of the Term shall be in a similar target
      range. Additional bonus calculations and payments determined by the Board and
      the Compensation Committee shall be made based upon (i) each $1 million in
      combined annual sales of the Corporation and its subsidiary BioCheck exceeding
      $6,500,000, (ii) successful financings an/or strategic transactions completed,
      taking into account the aggregate amount of funds raised for the Corporation
      and
      (iii) performance of the trading price of the Common Stock</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      bonuses payable hereunder shall be paid in cash, although at HAUSMAN&#8217;s sole
      option, they may be paid in stock (or in the form of ten year warrants with
      cashless exercise provisions, with 1.5 times the number of warrants to be issued
      in lieu of the number of shares of Common Stock), based upon the average of
      the
      closing bid and asked prices for the 5 trading days immediately prior to the
      awarding to HAUSMAN of the bonus for a particular year (which shall also be
      the
      exercise price of the warrants, if the Advisor elects to receive warrants).
      HAUSMAN shall make his election no more than ten (10) days following
      notification by the Corporation of his bonus award, and the failure to make
      timely election shall mean that HAUSMAN shall receive the bonus in the form
      of
      cash.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">2</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(ii)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Stock
      Options.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      As soon
      as practicable following execution of this Agreement, HAUSMAN shall be granted
      options for the purchase of up to 495,000 shares (the &#8220;Initial Option Grant&#8221;) of
      Common Stock under the Corporation&#8217;s existing stock option plan (the &#8220;Plan&#8221;).
      The terms of the grant, including the vesting schedule and exercise price of
      the
      Initial Option Grant, shall be as set forth in a separate option agreement
      executed by and between the parties and will provide, among other things, (i)
      for cashless exercise provisions and (ii) for the vesting of 247,500 options
      in
      four equal quarterly installments commencing on the date that is three months
      from the Commencement Date and every three months thereafter, (iii) for the
      vesting of the remaining 247,500 options in eight quarterly installments over
      the subsequent two years and (iv) for an exercise price equal to the average
      of
      the closing bid and asked prices for the Common Stock on the trading day
      immediately prior to the date hereof. Subsequent stock option grants, including
      an annual grant in 2007, will be determined annually by the Board and the
      Compensation Committee, taking into account the previous year&#8217;s performance of
      the Corporation&#8217;s Common Stock, sales, revenue and income performance, as well
      as the frequency and success of financings and/or strategic transactions.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 99pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(iii)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Additional
      Compensation</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
      The
      foregoing establishes the minimum compensation during the Term and shall not
      preclude the Board from awarding HAUSMAN a higher salary or any additional
      bonuses or stock options in the event of a successful financing or strategic
      transaction or otherwise, and in any event, in the discretion of the
      Board.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(iv)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Sign-on
      Bonus</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
      As a
      sign-on bonus and as soon as practicable following execution of this Agreement,
      , the Corporation shall issue to HAUSMAN 500,000 shares of Common Stock and
      ten
      year warrants (the &#8220;Warrants&#8221;) to purchase 1,505,000 shares of Common Stock, at
      an exercise price equal to the Market Price. The Warrants shall have a cashless
      exercise provision and otherwise shall be in form mutually satisfactory to
      the
      parties. All of the shares of Common Stock issued under this Section 3(b)(iv)
      will be subject to repurchase by the Corporation at a price of par value per
      share, and the amount of shares subject to repurchase will be reduced in six
      equal monthly increments commencing on the 30 days after the Commencement Date
      and every 30</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>th</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      day
      thereafter until 180 days after the Commencement Date, when none of such shares
      shall be subject to repurchase. The Warrants issued under this Section 3(b)(iv)
      will vest monthly in six equal installments, commencing on the date that is
      30
      days after the Commencement Date, through the 180</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>th</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      day
      after the Commencement Date. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>4.
      </strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Employee
      Benefits.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(a)</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>General.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During
      the Term, HAUSMAN shall be entitled to the employee benefits generally made
      available to the Corporation&#8217;s executive officers, including four-weeks paid
      vacation (no more than 2 weeks per month) and all U.S. national holidays,
      participation in the Corporation&#8217;s 401(k) plan or other plans that may be made
      available from time to time to the Corporation&#8217;s executive officers.
      Additionally, HAUSMAN shall receive family health and dental insurance benefits.
      As soon as reasonably practicable following the date hereof, the Corporation
      shall arrange for and maintain short-term and long-term disability policies
      for
      benefit of HAUSMAN in such amounts generally customary for similarly situated
      executive employees in the industry. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(b)</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Other
      Benefits. </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During
      the Term, the Corporation shall provide HAUSMAN with an annual office expense
      allowance of $50,000, for the costs of maintaining an office in the Stevenson,
      Washington area. The office expense allowance shall be payable quarterly in
      advance in the form of Common Stock, at a price equal to 85% of the Market
      Price. The first installment, representing $12,500 of the office expense
      allowance, will be paid promptly after the determination of the Market Price,
      and thereafter, will be paid on the dates that are three months, six months
      and
      nine months from the date hereof, and quarterly thereafter for the duration
      of
      the Term. Notwithstanding the foregoing, once the Corporation has completed
      a
      Qualifying Financing, the office expense allowance will be paid in cash in
      advance, commencing for the quarter next following the quarter in which the
      Qualifying Financing occurred.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">3</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(c)</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Indemnification.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      The
      Corporation will indemnify HAUSMAN for his actions in the capacity as an officer
      and director of the Corporation and any of its subsidiaries to the full extent
      permitted by law and as provided in the Corporation&#8217;s Certificate of
      Incorporation and by-laws. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 81pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>5</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Expenses.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      During
      the Term, the Corporation shall reimburse HAUSMAN in cash for actual
      out-of-pocket travel, entertainment and other business expenses incurred by
      him
      in the performance of his services for the Corporation upon the receipt of
      appropriate documentation of such expenses.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>6</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Termination;
      Non-Renewal.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>a</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>)
      </strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>General.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      The Term
      shall end immediately upon HAUSMAN&#8217;s death, or upon termination for Cause,
      Disability or Good Reason, each as defined in Section 7. Upon termination of
      the
      Term due to HAUSMAN&#8217;s death, all compensation due HAUSMAN under this Agreement
      will cease. In all other cases, (i) the Corporation may terminate this Agreement
      either upon sixty (60) days prior written notice, if such termination shall
      be
      effective in the calendar year 2006, or otherwise upon ninety (90) days written
      notice and (ii) HAUSMAN may terminate this Agreement upon sixty (60) days
      written notice. The parties agree that the mere act to providing notice to
      the
      other party of termination shall not in any event be deemed to provide such
      other party the right to immediately terminate this Agreement.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Corporation may elect not to renew this Agreement by giving no less than 90
      days
      written notice prior to the expiration of any Term. HAUSMAN may elect not to
      renew this Agreement by giving not less than 60 days written notice prior to
      the
      expiration of any Term. Upon the receipt of any notice of non-renewal as
      provided in this Section 6(a), HAUSMAN shall continue to be compensated in
      the
      manner set forth in this Agreement until the expiration of the applicable Term.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>b</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>)
      </strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Notice
      of Termination - Generally.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Any
      termination by the Corporation of HAUSMAN&#8217;s employment hereunder shall be in
      writing and delivered to HAUSMAN at the address set forth herein or at such
      address kept in the records of the Corporation and shall specify the reasons
      for
      such termination. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(c)</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Termination
      by the Corporation for Cause. </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Any
      written notice of termination by the Corporation of HAUSMAN for Cause shall,
      to
      the extent determined by the Board that the Cause is curable, allow HAUSMAN
      the
      opportunity to cure, but in any event no more than ten (10) days (except in
      the
      event of a termination pursuant to Section 7(a)(vi), in which case the cure
      period shall be 30 days). Such notice of termination shall also state in
      reasonable detail the Board&#8217;s understanding of the facts leading to the
      determination of Cause. Upon the Corporation&#8217;s final termination of the Term for
      Cause, all compensation due to HAUSMAN under this Agreement will cease, other
      than that described in Section 9 below. Moreover, any unexercised portions
      of
      the Initial Option Grant or other stock option grants to HAUSMAN by the
      Corporation shall expire upon such termination.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(d)</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Termination
      by the Corporation upon a Change of Control. </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      the
      event that the Corporation terminates its relationship with HAUSMAN within
      one
      (1) year of a &#8220;Change of Control&#8221;, as defined in Section 7(c), other than for
      Cause, HAUSMAN shall receive the following:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(i)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">an
      amount
      equal to twelve (12) months of base salary for the then current Term (which
      is
      in addition to the base salary paid to HAUSMAN after the Corporation&#8217;s delivery
      of notice of termination pursuant to Section 6 and the actual date of
      termination) plus an amount equal to the prior year&#8217;s bonus (and if occurring
      before the bonus for 2007 has been determined, an amount equal to 50% of the
      then current base salary); and</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">4</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(ii)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
      full
      vesting of the Initial Option Grant and any other stock option grants to HAUSMAN
      by the Corporation, and extended exercisability thereof until their respective
      expiration dates; and </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(iii)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other
      Compensation (as defined in Section 9); and</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(iv)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      the
      foregoing payments and benefits provided to HAUSMAN in Sections 6(d)(i) through
      (iii) above (the &#8220;Change of Control Payments&#8221;) are or become subject to the tax
      (&#8220;Excise Tax&#8221;) imposed by Section 4999 of the Internal Revenue Code of 1986, as
      amended, the Corporation shall pay to HAUSMAN such amount (the &#8220;Gross-up
      Payment&#8221;) as may be necessary to place HAUSMAN in the same after-tax position as
      if no portion of the Change of Control Payments and any amounts paid to him
      pursuant to this paragraph 6(d) had been subject to the Excise Tax.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      the
      avoidance of doubt, HAUSMAN shall be entitled to the foregoing benefits once
      notice of termination is given by the Corporation pursuant to this Section
      6(d),
      regardless of his subsequent Death or Disability.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(e)
      </strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Termination
      by the Corporation other than upon Change of Control, Death, Disability or
      Cause. </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      the
      event that the Corporation terminates its relationship with HAUSMAN, including
      a
      non-renewal of this Agreement by the Corporation but other than upon a Change
      of
      Control, Death, Disability or Cause, HAUSMAN shall receive the
      following:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: -72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(i)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">if
      employment was terminated during the calendar year 2006, an amount equal to
      six
      (6) months of the then current base salary; if employment was terminated
      commencing in the calendar year 2007 or if the Corporation elects not to renew
      this Agreement following the Initial Term or any Additional Term, an amount
      equal to twelve (12) months of base salary for the then current Term plus an
      amount equal to the prior year&#8217;s bonus (and if occurring before the bonus for
      2007 has been determined, an amount equal to 50% of the then current base
      salary) ; </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(ii)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">if
      employment was terminated during the calendar year 2006, 50% of the previously
      unvested portion of the Initial Option Grant shall vest and such vested options
      shall be exercisable until their respective expiration dates; if employment
      was
      terminated commencing in the calendar year 2007 and thereafter or if the
      Corporation elects not to renew this Agreement following the Initial Term or
      any
      Additional Term, all stock options granted to HAUSMAN (including without
      limitation the Initial Option Grant) shall immediately vest and shall remain
      exercisable until their respective expiration dates; and</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(iii)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other
      Compensation.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(f)
      </strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Termination
      by HAUSMAN upon Good Reason; Other Terminations. </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      the
      event HAUSMAN terminates his relationship with the Corporation for &#8220;Good Reason&#8221;
as defined in Section 7, within one (1) year of the occurrence of the event
      which established the &#8220;Good Reason,&#8221; or for &#8220;Good Reason&#8221; within one (1) year of
      a Change of Control, HAUSMAN shall receive the following:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: -36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(i)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">if
      the
      termination occurred during the calendar year 2006 for Good Reason, an amount
      equal to six (6) months of base salary; if the termination occurred during
      the
      calendar year 2006 due to a Change of Control, an amount equal to twelve (12)
      months of base salary; if termination for Good Reason occurred during the
      calendar year 2007 or thereafter, an amount equal to twelve (12) months of
      the
      then current base salary plus an amount equal to the prior year&#8217;s bonus (and if
      occurring before the bonus for 2007 has been determined, an amount equal to
      50%
      of the then current base salary); </font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">5</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(ii)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">if
      termination occurred during the calendar year 2006, 50% of the previously
      unvested portion of the Initial Option Grant shall vest and such vested options
      shall be exercisable until their respective expiration dates, except that if
      termination is by HAUSMAN for Good Reason subsequent to a Change of Control,
      then 100% of any option grants to HAUSMAN (including, without limitation, the
      Initial Option Grant) shall vest and shall remain exercisable until its
      respective expiration dates; if employment was terminated commencing in the
      calendar year 2007 and thereafter, all stock options granted to HAUSMAN
      (including, without limitation, the Initial Option Grant) shall immediately
      vest
      and shall remain exercisable until their respective expiration dates; and
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(iii)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other
      Compensation.</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">HAUSMAN
      shall provide prior written notice to the Corporation of his termination
      pursuant to this Section 6(f), and such notice shall describe the particular
      &#8220;Good Reason(s)&#8221; at issue.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      HAUSMAN otherwise terminates his employment without Good Reason, all options
      vested at the time of such termination shall expire on their respective
      expiration dates.</font></div>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>7.
      </strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Definitions.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>a</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>)
      </strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>"Cause"
      Defined.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;Cause&#8221;
      means (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">i</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)
      willful
      malfeasance or willful misconduct by HAUSMAN in connection with his employment;
      (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ii</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)
      HAUSMAN&#8217;s gross negligence in performing any of his duties under this Agreement;
      (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">iii</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)
      HAUSMAN&#8217;s conviction of, or entry of a plea of guilty to, or entry of a plea of
      nolo contendere with respect to, any felony; (iv) HAUSMAN&#8217;s habitual drunkenness
      or use or possession of illegal drugs while performing his duties under this
      Agreement or excessive absenteeism not related to illness; (v) HAUSMAN&#8217;s
      material breach of any written policy applicable to all employees adopted by
      the
      Corporation; or (vi) material breach by HAUSMAN of any of his agreements in
      this
      Agreement having a material detrimental impact on the Corporation.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(b)
      </strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#8220;Disability&#8221;
      Defined.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;Disability&#8221;
      shall mean HAUSMAN&#8217;s incapacity due to physical or mental illness that results
      in his being unable to substantially perform his duties hereunder for six
      consecutive months (or for six months out of any nine-month period). During
      a
      period of Disability, HAUSMAN shall continue to receive his base salary
      hereunder, provided that if the Corporation provides HAUSMAN with disability
      insurance coverage, payments of HAUSMAN&#8217;s base salary shall be reduced by the
      amount of any disability insurance payments received by HAUSMAN due to such
      coverage. Upon termination, after the end of the period of Disability, all
      compensation due HAUSMAN under this Agreement shall cease.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(c)
      </strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#8220;Change
      of Control&#8221; Defined. </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;Change
      of Control&#8221; shall mean the occurrence of any one or more of the following
      events:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(i)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">An
      acquisition (whether directly from the Corporation or otherwise) of any voting
      securities of the Corporation (the &#8220;Voting Securities&#8221;) by any &#8220;Person&#8221; (as the
      term person is used for purposes of Section 13(d) or 14(d) of the Securities
      and
      Exchange Act of 1934, as amended (the &#8220;1934 Act&#8221;)), immediately after which such
      Person has &#8220;Beneficial Ownership&#8221; (within the meaning of Rule 13d-3 promulgated
      under the 1934 Act) of fifty percent (50 %) or more of the combined voting
      power
      of the Corporation&#8217;s then outstanding Voting Securities.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 81pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(ii)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      individuals who, as of the Commencement Date, are members of the Board (the
      &#8220;Incumbent Board&#8221;), cease for any reason to constitute at least fifty-one
      percent (51%) of the Board; or</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">6</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(iii)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Approval
      by the Board and, if required, stockholders of the Corporation of, or execution
      by the Corporation of any agreement with respect to, or the consummation of
      (it
      being understood that the mere execution of a term sheet, memorandum of
      understanding or other non-binding document shall not constitute a Change of
      Control):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 144pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(A)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
      merger,
      consolidation or reorganization involving the Corporation, where either or
      both
      of the events described in Section 7(c)(i) or 7(c)(ii) would be the
      result;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 144pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(B)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
      liquidation or dissolution of or appointment of a receiver, rehabilitator,
      conservator or similar person for, the Corporation; or</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 144pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(C)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">An
      agreement for the sale or other disposition of all or substantially all of
      the
      assets of the Corporation to any Person (other than a transfer to a subsidiary
      of the Corporation).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Notwithstanding
      anything contained in this Agreement to the contrary, if HAUSMAN&#8217;s employment is
      terminated prior to a Change in Control and HAUSMAN reasonably demonstrates
      that
      such termination (i) was at the request of a third party who has indicated
      an
      intention or taken steps reasonably calculated to effect a Change in Control
      and
      who effectuates a Change in Control (a &#8220;Third Party&#8221;) or (ii) otherwise occurred
      in connection with, or in anticipation of, a Change in Control which actually
      occurs, then for all purposes of this Agreement, the date of a Change in Control
      with respect to HAUSMAN shall mean the date immediately prior to the date of
      such termination of HAUSMAN&#8217;s employment.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(d)
      </strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#8220;Good
      Reason&#8221; Defined. </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;Good
      Reason&#8221; shall mean the occurrence, whether or not after a Change in Control, of
      any of the events or conditions described below:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(i)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a
      change
      in HAUSMAN&#8217;s status, title, position or responsibilities (including reporting
      responsibilities) which represents a material adverse change from his status,
      title, position or responsibilities as in effect immediately prior to such
      change; the assignment to HAUSMAN of any duties or responsibilities which are
      inconsistent with his status, title, position or responsibilities as in effect
      immediately prior to such change; or any removal of HAUSMAN from any of such
      offices or positions (except in those cases where a change is either at the
      request of HAUSMAN, in connection with a general corporate restructuring of
      officer responsibilities, or a result of the promotion of HAUSMAN);</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(ii)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
      Corporation&#8217;s requiring HAUSMAN to spend substantially all of his time
      performing his duties hereunder at a location other than his current home office
      facility, including requiring him to relocate to Foster City or the San
      Francisco area, except for required travel relating to the Corporation&#8217;s
      business;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 117pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(iii)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
      failure by the Corporation to provide HAUSMAN with benefits, in the aggregate,
      at least equal (in terms of benefit levels) to those provided for under each
      employee benefit plan, program and practice in which HAUSMAN was participating
      at any time prior to such failure; or</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(iv)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">any
      material breach by the Corporation of any provision of this Agreement which
      is
      not cured within ten (10) days after the receipt of written notice by the
      Corporation of a description of the breach. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>8.</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Payment
      Terms.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Payment
      of any amounts to which HAUSMAN shall be entitled pursuant to the provisions
      of
      Sections 6 and 7 shall be made no later than sixty (60) days following receipt
      of notice of termination or the event giving rise to such termination. Any
      amounts payable pursuant to Sections 6 and 7 which are not made within the
      period specified in this Section 8 shall bear interest at a rate equal to the
      lesser of (i) the maximum interest rate allowable pursuant to applicable law
      or
      (ii) five points above the &#8220;prime rate&#8221; of interest as published from
      time-to-time in the Eastern Edition of the Wall Street Journal.</font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">7</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>9.</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Post-Termination
      Benefits.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      benefits hereunder shall be deemed the &#8220;Other Compensation&#8221; referenced in
      Section 6(d), 6(e) and 6(f) hereof. Except if HAUSMAN resigns without Good
      Reason (other than retirement on or after the age of 62), in the event HAUSMAN&#8217;s
      employment with the Corporation is terminated for any reason prior to the end
      of
      the Term, HAUSMAN and his dependents, if any, will continue to participate
      in
      any group health plan sponsored by the Corporation in which HAUSMAN was
      participating on the date of such termination,</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">at
      a cost
      to HAUSMAN and his dependents equal to the amount charged by the Corporation
      to
      similarly situated employees while employed by the Corporation, for the
      remainder of the Initial Term or, if termination occurs within an Additional
      Term, for the remainder of such Additional Term. Thereafter, HAUSMAN and his
      dependents, if any, shall be entitled to elect to continue such health coverage,
      at a cost to HAUSMAN and his dependents equal to the amount paid by the
      Corporation for similarly situated employees while employed by the Corporation,
      for the longest period of time permitted by the agents of the Corporation who
      arrange for such health coverage, with such period to last at least twelve
      (12)
      months from the date of termination. Upon termination for any reason, in
      addition to any payments to which HAUSMAN may be entitled upon termination
      of
      his Employment pursuant to any provision of this Agreement, HAUSMAN shall be
      entitled to any benefits under any pension, supplemental pension, savings,
      or
      other employee benefit plan (other than life insurance) in which HAUSMAN was
      participating on the date of any such termination.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>10.
      </strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Confidentiality.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>a</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>)
      </strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>"Corporation
      Information" Defined.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;Corporation
      Information&#8221; means all information, knowledge or data of or pertaining to (i)
      the Corporation, its employees and all work undertaken on behalf of the
      Corporation, and (ii) any other person, firm, corporation or business
      organization with which the Corporation may do business during the Term, that
      is
      not in the public domain (and whether relating to methods, processes,
      techniques, discoveries, pricing, marketing or any other matters). </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>b</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>)</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Confidentiality.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      HAUSMAN
      hereby recognizes that the value of all trade secrets and other proprietary
      data
      and all other information of the Corporation not in the public domain disclosed
      by the Corporation in the course of his employment with the Corporation is
      attributable substantially to the fact that such confidential information is
      maintained by the Corporation in strict confidentiality and secrecy and would
      be
      unavailable to others without the expenditure of substantial time, effort or
      money. HAUSMAN therefore, except as provided in the next two sentences,
      covenants and agrees that all Corporation Information shall be kept secret
      and
      confidential at all times during and after the end of the Term and shall not
      be
      used or divulged by him outside the scope of his employment as contemplated
      by
      this Agreement, except as the Corporation may otherwise expressly authorize
      by
      action of the Board. In the event that HAUSMAN is requested in a judicial,
      administrative or governmental proceeding to disclose any of the Corporation
      Information, HAUSMAN will promptly so notify the Corporation so that the
      Corporation may seek a protective order or other appropriate remedy and/or
      waive
      compliance with this Agreement. If disclosure of any of the Corporation
      Information is required, HAUSMAN may furnish the material so required to be
      furnished, but HAUSMAN will furnish only that portion of the Corporation
      Information that legally is required. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">8</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>11.</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Non-Competition,
      Non-disparagement and Non-Solicitation Covenants; Intellectual Property.
</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(a)</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Non-Competition.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Corporation and HAUSMAN acknowledge that: (i) the Corporation has a special
      interest in and derives significant benefit from the unique skills and
      experience of HAUSMAN; (ii) HAUSMAN will use and have access to proprietary
      and
      valuable Corporation Information (as defined in Section 10 hereof) during the
      course of his employment; and (iii) the agreements and covenants contained
      herein are essential to protect the business and goodwill of the Corporation
      or
      any of its subsidiaries, affiliates or licensees. Accordingly, except as
      hereinafter noted, HAUSMAN covenants and agrees that during the Term, and for
      a
      period of one year following the termination of HAUSMAN&#8217;s employment, HAUSMAN
      shall not provide any labor, work, services or assistance (whether as an
      officer, director, employee, partner, agent, owner, independent contractor,
      stockholder or otherwise) to a &#8220;Competing Business.&#8221; For purposes hereof,
&#8220;Competing Business&#8221; shall mean any business engaged in (i) the research,
      diagnosis, treatment and prevention of diseases of oxidative stress associated
      with damage from free radical and reactive oxygen species or (ii) the provision
      of high quality enzyme immunoassay research services and products including
      immunoassay kits for cardiac and tumor markers, infectious diseases, thyroid
      function, steroids, and fertility hormones</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">or
      any
      other business engaged in by the Company during the Term. Notwithstanding the
      foregoing, a &#8220;Competing Business&#8221; shall not include any of the business
      activities identified on Schedule A annexed hereto, activities which the
      Corporation hereby acknowledges do not constitute corporate opportunities of
      the
      Corporation and in which HAUSMAN has previously engaged and may continue to
      engage. In consideration of all of the compensation provisions in this
      Agreement, HAUSMAN agrees to the provisions of this Section 11 and also agrees
      that the non-competition obligations imposed herein, are fair and reasonable
      under all the circumstances.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(b)</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Non-Solicitation
      of Employees</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
      HAUSMAN
      covenants and agrees that during the Term, and for a period of one year
      following termination of employment hereunder for any reason whatsoever, HAUSMAN
      shall not directly or indirectly solicit any other employee of or consultant
      to
      the Corporation, or any of its subsidiaries or affiliates to terminate such
      employee&#8217;s employment or consultant&#8217;s relationship with the Corporation, or any
      of its subsidiaries or affiliates, as the case may be, or to become employed
      by
      or a consultant to a Competing Business.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(c)</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Ownership
      of Intellectual Property.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Any
      material or other work which may be subject to copyright or patent, and which
      is
      conceived, derived, made or written by HAUSMAN in connection with the
      Corporation Information shall be deemed a &#8220;work for hire,&#8221; (and is herein
      referred to as a &#8220;Development&#8221;). As between HAUSMAN and the Corporation, HAUSMAN
      acknowledges that all Developments will be the sole and exclusive property
      of
      the Corporation and shall also be deemed Corporation Information under this
      Agreement. HAUSMAN further acknowledges the Corporation may in turn negotiate
      with any third party regarding their respective ownership rights to such
      Developments. HAUSMAN shall execute such documents as may be necessary to vest
      in the Corporation or any third party, if applicable, all right, title and
      interest in and to the Developments. The Corporation (or a third party, if
      applicable) will pay all costs and expenses associated with any applications
      and
      the transfer of title to Developments, including paying HAUSMAN&#8217;s reasonable
      attorneys&#8217; fees for reviewing such documents and instruments presented for
      execution. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(d)</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>HAUSMAN&#8217;s
      Intellectual Property Rights. </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Notwithstanding
      the foregoing, the assignment by HAUSMAN to the Corporation (or a third party,
      if applicable) of Developments, as well as the right to apply for and obtain
      patents and/or registered copyrights on the same, shall be expressly limited
      to
      those specifically involving the Corporation Information relating to such
      projects as mutually agreed upon by the parties hereto, and shall specifically
      not include (i) any right, license or interest of the Corporation to general
      concepts, formats, methods, testing techniques, study designs, computer software
      or other procedures utilized or designed by HAUSMAN in performing his duties
      hereunder, or any general inventions, discoveries, improvements, or
      copyrightable materials relating thereto, nor (ii) any patentable or
      copyrightable materials which can be shown by competent proof not to concern
      the
      subject matter of the Corporation Information, or, which predate this Agreement
      or HAUSMAN&#8217;s receipt of the Corporation Information, or (iii) any intellectual
      property relating to HAUSMAN&#8217;s current activities identified on Schedule
      A.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">9</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(e)</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Remedies</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
      HAUSMAN
      acknowledges that any such breach of the provisions of this Section 11 is likely
      to result in immediate and irreparable harm to the Corporation for which money
      damages are likely to be inadequate. Accordingly, HAUSMAN consents to injunctive
      and other appropriate equitable relief upon the institution of proceedings
      therefor by the Corporation in order to protect its rights hereunder. Such
      relief may include, without limitation, an injunction to prevent: (i) the breach
      or continuation of HAUSMAN&#8217;s breach; (ii) HAUSMAN from disclosing any trade
      secrets or Corporation Information; (iii) any Competing Business from receiving
      from HAUSMAN or using any such trade secrets or Corporation Information; and/or
      (iv) any such Competing Business from retaining or seeking to retain any
      employees of the Corporation. The provisions of this Section 11(e) shall survive
      the termination of this Agreement and HAUSMAN&#8217;s Term of employment.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>12.</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Successors
      and Assigns; Expenses.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>a</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>)</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>The
      Employee.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      This
      Agreement is a personal contract, and the rights and interests that the
      Agreement accords to HAUSMAN may not be sold, transferred, assigned, pledged,
      encumbered, or hypothecated by him. All rights and benefits of HAUSMAN shall
      be
      for the sole personal benefit of HAUSMAN, and no other person shall acquire
      any
      right, title or interest under this Agreement by reason of any sale, assignment,
      transfer, claim or judgment or bankruptcy proceedings against HAUSMAN. Except
      as
      so provided, this Agreement shall inure to the benefit of and be binding upon
      HAUSMAN and his personal representatives, distributees and
      legatees.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>b</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>)</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>The
      Corporation. </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      Agreement shall be binding upon the Corporation and inure to the benefit of
      the
      Corporation and its successors and assigns. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(c)</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Expenses.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      costs
      of HAUSMAN&#8217;s counsel, Adam Eilenberg, related to the negotiation, preparation
      and review of this Agreement, in the amount of $5,000, shall be paid by the
      Corporation, in the form of shares of Common Stock, based on a price equal
      to
      85% of the Market Price, and shall be issued to Adam Eilenberg. Any shares
      issued pursuant to the foregoing sentence shall have the same registration
      rights as those being provided to HAUSMAN hereunder and pursuant to the
      Registration Rights Agreement. Furthermore, in the event of any dispute between
      HAUSMAN and the Corporation relating to this Agreement which follows a Change
      of
      Control, the Corporation will pay all reasonable legal expenses incurred by
      HAUSMAN in connection with such dispute unless a court of competent jurisdiction
      determines that the facts surrounding such dispute originates from events that
      occurred prior to the Change of Control.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>13.</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Entire
      Agreement.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      This
      Agreement, together with the Initial Option Grant and the Registration Rights
      Agreement, represents the entire agreement between the parties concerning
      HAUSMAN&#8217;s employment with the Corporation and supersedes all prior negotiations,
      discussions, understandings and agreements, whether written or oral, between
      HAUSMAN and the Corporation relating to the subject matter of this Agreement,
      including any existing consulting agreements.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>14.</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Amendment
      or Modification; Waiver.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      No
      provision of this Agreement may be amended or waived unless such amendment
      or
      waiver is agreed to in writing signed by HAUSMAN and by a duly authorized
      officer of the Corporation. No waiver by any party to this Agreement of any
      breach by another party of any condition or provision of this Agreement to
      be
      performed by such other party shall be deemed a waiver of a similar or
      dissimilar condition or provision at the same time, any prior time or any
      subsequent time.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">10</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>15.</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Notices.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Any
      notice to be given under this Agreement shall be in writing and delivered
      personally or sent by overnight courier or registered or certified mail, postage
      prepaid, return receipt requested, addressed to the party concerned at the
      address indicated below, or to such other address of which such party
      subsequently may give notice in writing:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      to
      HAUSMAN:</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">MARVIN
      S.
      HAUSMAN, M.D </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 180pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">90
      NW
      Second Street, P.O. Box 910, </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 180pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Stevenson,
      Washington 98648</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 180pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">with
      a
      copy to:</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;Eilenberg
      &amp; Krause LLP</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 180pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">11
      East
      44</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>th</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Street</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 180pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">New
      York,
      NY 10017</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 180pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Attention:
      Adam Eilenberg, Esq.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 180pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      to the
      Corporation:</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">OXIS
      International, Inc. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 180pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">323
      Vintage Park Drive, Suite B, </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 180pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Foster
      City, California 94404</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 180pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Attention:
      Chairman of the Board </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">with
      a
      copy to:</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">__________________________</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">__________________________</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">__________________________</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 180pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Attention:
      __________________</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Any
      notice delivered personally or by overnight courier shall be deemed given on
      the
      date delivered and any notice sent by registered or certified mail, postage
      prepaid, return receipt requested, shall be deemed given on the date
      mailed.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>16.</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Severability.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      If any
      provision of this Agreement or the application of any such provision to any
      party or circumstances shall be determined by any court of competent
      jurisdiction to be invalid and unenforceable to any extent, the remainder of
      this Agreement or the application of such provision to such person or
      circumstances other than those to which it is so determined to be invalid and
      unenforceable shall not be affected, and each provision of this Agreement shall
      be validated and shall be enforced to the fullest extent permitted by law.
      If
      for any reason any provision of this Agreement containing restrictions is held
      to cover an area or to be for a length of time that is unreasonable or in any
      other way is construed to be too broad or to any extent invalid, such provision
      shall not be determined to be entirely null, void and of no effect; instead,
      it
      is the intention and desire of both the Corporation and HAUSMAN that, to the
      extent that the provision is or would be valid or enforceable under applicable
      law, any court of competent jurisdiction shall construe and interpret or reform
      this Agreement to provide for a restriction having the maximum enforceable
      area,
      time period and such other constraints or conditions (although not greater
      than
      those contained currently contained in this Agreement) as shall be valid and
      enforceable under the applicable law.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>17.</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Survivorship.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      The
      respective rights and obligations of the parties hereunder shall survive any
      termination of this Agreement to the extent necessary to the intended
      preservation of such rights and obligations.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">11</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>18.</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Headings.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      All
      descriptive headings of sections and paragraphs in this Agreement are intended
      solely for convenience of reference, and no provision of this Agreement is
      to be
      construed by reference to the heading of any section or paragraph.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>19.</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Withholding
      Taxes.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      All
      salary, benefits, reimbursements and any other payments to HAUSMAN under this
      Agreement shall be subject to all applicable payroll and withholding taxes
      and
      deductions required by any law, rule or regulation of and federal, state or
      local authority. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>20.
      </strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Counterparts.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      This
      Agreement may be executed in one or more counterparts, each of which shall
      be
      deemed to be an original but all of which together constitute one and same
      instrument.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>21.</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Applicable
      Law; Jurisdiction.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      The laws
      of the State of California shall govern the interpretation, validity and
      performance of the terms of this Agreement, without reference to rules relating
      to conflicts of law. Any suit, action or proceeding against HAUSMAN with respect
      to this Agreement, or any judgment entered by any court in respect thereof,
      may
      be brought in any court of competent jurisdiction in the State of California,
      as
      the Corporation may elect in its sole discretion, and HAUSMAN hereby submits
      to
      the exclusive jurisdiction of such courts for the purpose of any such suit,
      action, proceeding or judgment.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>[THE
      BALANCE OF THIS PAGE HAS BEEN LEFT BLANK INTENTIONALLY]</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">12</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">IN
      WITNESS WHEREOF, the parties hereto have executed this Agreement as of the
      date
      first written above.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 180pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;</font>___<u><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">s/
      Marvin
      S. Hausman, M.D.</font></u>_______</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 180pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;MARVIN
      S. HAUSMAN,
      M.D. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 180pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;OXIS
      INTERNATIONAL,
      INC. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 180pt;">&#160;</td>
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;By:</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">____<u>/s/
                Michael D. Centron</u>_____________</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;</font>Name:
      Michael D.
      Centron</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;</font>Title:
      Vice President &amp;
CFO</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>&#160;</div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">13</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SCHEDULE
      A</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PERMITTED
      OUTSIDE BUSINESS ACTIVITIES OF HAUSMAN</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 18pt;">&#160;</td>
            <td style="width: 18pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">HAUSMAN&#8217;s
                previously disclosed current activities in the field of mushrooms
                and
                associated oxidative stress and bioactive substances, as well as
                to the
                avian flu virus, previously acknowledged by the Board not to constitute
                business opportunities of the Corporation.
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 18pt;">&#160;</td>
            <td style="width: 18pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Patent
                activity, research and development and commercial development of
                patent
                applications and related intellectual property entitled &#8220;Identification of
                Selenoergothioneine as a Natural Organic Form of Selenium from Cultivated
                Mushrooms&#8221; for which HAUSMAN is a
                co-inventor.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 18pt;">&#160;</td>
            <td style="width: 18pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Patent
                activity, research and development and commercial development of
                patent
                applications and related intellectual property entitled &#8220;Identification of
                ergothioneine transporter and therapeutic uses thereof&#8221; to which HAUSMAN
                and related entities have acquired rights.
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">14</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div>
        <hr style="COLOR: black" align="center" noshade size="2" width="100%">
      </div><br></div>
  </body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>advisoryagreement.htm
<DESCRIPTION>ADVISORY AGREEMENT BETWEEN OXIS INTERNATIONAL, INC. AND AMBIENT ADVISORS, LLC DATED NOVEMBER 6, 2006
<TEXT>
<html>
  <head>
    <title>
      Advisory Agreement between OXIS International, Inc. and Ambient Advisors, LLC
      dated November 6, 2006
</title>
<!-- Licensed to: OXIS International, Inc.-->
<!-- Document Created using EDGARizer HTML 3.0.4.0 -->
<!-- Copyright 2006 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Exhibit
      10.2</strong></font></div>
    <div><br>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ADVISORY
      AGREEMENT </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">dated
      as
      of November 6, 2006, between Oxis International, Inc., a Delaware corporation
      (the &#8220;Company&#8221;), and Ambient Advisors LLC (the &#8220;Advisor&#8221;).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company desires to retain the Advisor to provide management and advisory
      services to the Company, and the Advisor desires to perform such management
      and
      advisory services for the Company, in each case, upon the terms and conditions
      hereinafter set forth. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>NOW,
      THEREFORE,</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      in
      consideration of the mutual covenants and obligations hereinafter set forth,
      the
      parties agree as follows:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>1.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Retention
      of Advisor</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company hereby retains the Advisor, and the Advisor hereby accepts such
      retention by the Company, upon the terms and conditions hereinafter set forth.
      The Advisor shall perform all such services as an independent contractor to
      the
      Company and not as an employee, agent or representative of the
      Company.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Term</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      retention of the Advisor hereunder shall be for a period (the &#8220;Initial Term&#8221;)
      that commenced on October 15, 2006 (the &#8220;Commencement Date&#8221;) and shall end on
      October 15, 2009 or such earlier date provided in this Section 2. The Initial
      Term will be extended automatically for additional one-year periods (each an
      &#8220;Additional Term,&#8221; together with the Initial Term, the &#8220;Term&#8221;). This Agreement
      shall automatically terminate prior to October 15, 2009 or the expiration of
      any
      Additional Term upon the first to occur of (i) the death or disability of Mr.
      Gary M. Post, Managing Director of the Advisor, (ii) the resignation by the
      Advisor following the delivery by it to the Company of ten days&#8217; advance written
      notice of such resignation or (iii) termination by the Company following the
      delivery to the Advisor of 60 days&#8217; advance written notice from the Company&#8217;s
      Board of Directors of its intention to terminate the Agreement. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Duties</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During
      the Term, the Advisor shall advise the Company and provide management services
      in the areas of (a) strategic planning, (b) financial planning and budgeting,
      (c) investor relations, (d) corporate finance (including advising on new capital
      formation and mergers and acquisitions), (e) day to day operational management
      and (f) such additional roles and responsibilities as the Advisor and the
      Company shall mutually agree. The parties acknowledge that Mr. Gary M. Post
      shall perform substantially all of the services of the Advisor under this
      Agreement, and that although he will not formally be named an officer of the
      Company, he will be empowered to sign checks and enter into contracts on the
      Company&#8217;s behalf in the capacity of &#8220;Acting Chief Operating Officer.&#8221; The
      Advisor shall report directly to, and shall reasonably update, the CEO or his
      designee on the status of each project, and shall reasonably coordinate its
      efforts with members of management, the Board of Directors and other advisors
      and consultants to the Company. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>4.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Time
      to be Devoted to Services</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During
      the Term, the Advisor agrees to spend approximately one-third (1/3) of the
      Advisor&#8217;s working time to the provisions of services hereunder.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>5.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Compensation</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(a)</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Advisory
      Fee</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company shall pay to the Advisor an advisory fee of $83,333 per annum. The
      advisory fee initially will be payable quarterly in advance in the form of
      either the Company&#8217;s common stock (&#8220;Common Stock&#8221;), at a price equal to 85% of
      the &#8220;Market Price&#8221; for the Company&#8217;s common stock, which shall equal the average
      of the closing price for the five trading days prior to the date that the
      issuance is authorized by the Board of Directors. In lieu of receiving Common
      Stock for such payments, the Advisor may elect to receive that number of ten
      year Warrants (with cashless exercise provisions) equal to 1.5 times the number
      of shares of Common Stock that would otherwise be received, at an exercise
      price
      equal to the Market Price. The first installment, representing $20,833 of the
      annual advisory fee, and payable at the Advisor&#8217;s election in the form of
      warrants described in the foregoing sentence, will be made as soon as
      practicable after the execution of this Agreement, and thereafter, will be
      paid
      on the dates that are three months, six months and nine months from the date
      hereof, and quarterly thereafter for the duration of the Term. Notwithstanding
      the foregoing, once the Company has raised at least $2.5 million in one or
      more
      financings (equity, debt or convertible debt, in addition to the financing
      closed on October 27, 2006) or in a strategic transaction (a &#8220;Qualifying
      Financing&#8221;), the Advisor may elect, at any time, in lieu of receiving a
      quarterly issuance of stock (or warrants in lieu thereof), to receive the
      advisory fee in cash, payable monthly on the Corporation&#8217;s regular pay cycle for
      professional employees. All shares of Common Stock issuable to the Advisor
      under
      this Agreement (if not otherwise registered pursuant to an existing stock option
      plan covered by a registration statement on Form S-8), or upon the exercise
      of
      the warrants to be issued in lieu thereof, shall have the benefit of piggyback
      registration rights, pursuant to a Registration Rights Agreement to be executed
      by the Company and the Advisor (the &#8220;Registration Rights Agreement&#8221;); provided,
      however, that the failure to execute such a Registration Rights Agreement shall
      not limit the Advisor&#8217;s piggyback registration rights hereunder. Following the
      Initial Term, the Board shall in accordance with its customary review of
      executive management and consultants&#8217; compensation, review Advisor&#8217;s annual
      advisory fee and make adjustments the Board (or its Compensation Committee)
      feels are appropriate, but in any event Advisor&#8217;s base compensation shall not be
      lower than $250,000 (on a full-time annual basis).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(b)
      Other and Additional Compensation.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(i)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Annual
      Bonus.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      During
      the Term, the Advisor shall receive an annual bonus based upon the attainment
      of
      agreed upon goals and milestones as determined by the Board and its Compensation
      Committee. During the remainder of calendar year 2006, the Advisor&#8217;s bonus shall
      be pro rated on an annual bonus rate in the range of 25% to 50% of the advisory
      fee, and the bonus for subsequent years of the Term shall be in a similar target
      range. Additional bonus calculations and payments determined by the Board and
      the Compensation Committee shall be made based upon (i) increases in the
      Company&#8217;s sales and reductions in its expenses, improvements in operations, and
      completion of a merger with Biochek and integration of its operations with
      those
      of the Company, (ii) successful financings an/or strategic transactions
      completed, taking into account the aggregate amount of funds raised for the
      Company and (iii) performance of the trading price of the Company&#8217;s Common
      Stock</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      bonuses payable hereunder shall be paid in cash, although at the Advisor&#8217;s sole
      option, they may be paid in stock (or in the form of ten year warrants with
      cashless exercise provisions, with 1.5 times the number of warrants to be issued
      in lieu of the number of shares of Common Stock), based upon the average of
      the
      closing bid and asked prices for the 5 trading days immediately prior to the
      awarding to the Advisor of the bonus for a particular year (which shall also
      be
      the exercise price of the warrants, if the Advisor elects to receive warrants).
      The Advisor shall make its election no more than ten (10) days following
      notification by the Company of the bonus award, and the failure to make timely
      election shall mean that the Advisor shall receive the bonus in the form of
      cash.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">2</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(ii)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Warrants.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      As soon
      as practicable following execution of this Agreement, the Company shall issue
      to
      the Advisor ten year warrants to purchase 550,000 shares of Common Stock (the
      &#8220;Warrants&#8221;), at an exercise price equal to the Market Price. The Warrants shall
      have a cashless exercise provision and otherwise shall be in form mutually
      satisfactory to the parties. The Warrants will vest as follows: 275,000 Warrants
      in four equal quarterly installments commencing on the date that is three months
      from the Commencement Date and every three months thereafter, (iii) and the
      remaining 275,000 Warrants in eight quarterly installments over the subsequent
      two years and (iv) for an exercise price equal to the average of the closing
      bid
      and asked prices for the Common Stock on the trading day immediately prior
      to
      the date of the execution of this Agreement.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 99pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(iii)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Additional
      Compensation</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
      The
      foregoing establishes the minimum compensation during the Term and shall not
      preclude the Board from awarding the Advisor a higher salary or any additional
      bonuses or stock options in the event of a successful financing or strategic
      transaction or otherwise, and in any event, in the discretion of the Board.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(iv)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Sign-on
      Bonus</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
      As a
      sign-on bonus and as soon as practicable following execution of this Agreement,
      the Advisor shall be granted non-qualified options for the purchase of up to
      333,333 shares (the &#8220;Initial Option Grant&#8221;) of Common Stock under the Company&#8217;s
      existing stock option plan (the &#8220;Plan&#8221;). The terms of the grant, including the
      vesting schedule and exercise price of the Initial Option Grant, shall be as
      set
      forth in a separate option agreement executed by and between the parties and
      will provide, among other things, (i) for cashless exercise provisions and
      (ii)
      for the vesting in six equal installments, commencing on the date that is 30
      days after the Commencement Date, through the 180</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>th</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      day
      after the Commencement Date. The options issued under this Section 5(b)(iv)
      will
      vest monthly in six equal installments, commencing on the date that is 30 days
      after the Commencement Date, through the 180</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>th</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      day
      after the Commencement Date. Subsequent stock option grants, including an annual
      grant in 2007, will be determined annually by the Board and the Compensation
      Committee, taking into account the previous year&#8217;s performance of the Company&#8217;s
      Common Stock, sales, revenue and income performance, as well as the frequency
      and success of financings and/or strategic transactions. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>6.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Business
      Expenses: Benefits</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
      The
      Company shall reimburse the Advisor in cash, in accordance with its practice
      from time to time, for all reasonable and necessary travel, entertainment and
      other expenses and other disbursements incurred by the Advisor for or on behalf
      of the Company in the performance of the Advisor&#8217;s duties hereunder. The Advisor
      shall provide such appropriate documentation of expenses and disbursements
      as
      may from time to time be required by the Company. Any travel expenses in excess
      of $1,000 for any one trip must be pre-approved by the CEO.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company shall have no obligation to provide any benefits to Advisor or to Gary
      M. Post, including without limitation, any health, life or disability
      benefits.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>7.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Indemnification;
      Insurance</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company will indemnify the Advisor for its actions in the capacity as a Advisor
      hereunder (other than resulting from the Advisor&#8217;s gross negligence or willful
      misconduct) and Gary M. Post for his actions as a director of the Company and
      any of its subsidiaries to the full extent permitted by law and as provided
      in
      the Company&#8217;s Certificate of Incorporation and by-laws. The Company also will
      include the Advisor and Gary M. Post on its existing Directors and Officers
      liability insurance policy, which the Company represents is for a customary
      amount for similar public companies in the life sciences
      industry.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">3</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>8.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Termination
      Payments</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      the
      Company terminates this Agreement pursuant to Section 2(iii) without Cause
      after
      the six month anniversary of the date of this Advisory Agreement, Advisor shall
      receive an amount equal to twelve (12) months of the advisory fee for the then
      current Term in a lump sum payment and all outstanding stock options shall
      become fully vested and the warrants vested as of the date of termination and
      the stock options shall remain exercisable through their respective expiration
      dates. If the Company terminates this Agreement pursuant to Section 2(iii)
      without Cause prior the six month anniversary of the date of this Advisory
      Agreement, Advisor shall be paid any expenses due to him and all vested stock
      options and warrants shall remain exercisable through their respective
      expiration dates. &#8220;Cause&#8221; shall mean means (i) willful malfeasance or willful
      misconduct by the Advisor in connection with the performance of its duties
      hereunder; (ii) the Advisor&#8217;s gross negligence in performing any of its duties
      under this Agreement; (iii) the Advisor&#8217;s or Gary M. Post&#8217;s conviction of, or
      entry of a plea of guilty to, or entry of a plea of nolo contendere with respect
      to, any felony; (iv) the habitual drunkenness or use or possession of illegal
      drugs by Gary M. Post while performing the Advisor&#8217;s duties under this Agreement
      or excessive absenteeism not related to illness; (v) the Advisor&#8217;s material
      breach of any written policy applicable to all employees and Advisors adopted
      by
      the Corporation; or (vi) material breach by the Advisor of any of its agreements
      in this Agreement having a material detrimental impact on the Company after
      written notice and a reasonable opportunity to cure of not less than 30
      days.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      the
      Company terminates this Agreement pursuant to Section 2(iii) for Cause, the
      Company will only be required to give ten (10) days&#8217; prior notice (other than
      pursuant to Section 8(a)(vi), for which the notice requirement is 30 days),
      stating in reasonable detail the Board&#8217;s understanding of the facts leading to
      the determination of Cause, and in such event the Advisor shall not be entitled
      to any further payments of its advisory fee hereunder, and any unexercised
      stock
      options shall expire.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      the
      Advisor resigns pursuant to Section 2(ii), for whatever reason, or if Gary
      M.
      Post dies or becomes disabled, the Advisor (or its successors or assigns) shall
      not be entitled to any further payments of the advisory fee hereunder, all
      unvested stock options and warrants shall expire, and all vested stock options
      and warrants shall remain exercisable until their respective expiration dates.
      &#8220;Disability&#8221; shall mean the incapacity of Gary Post due to physical or mental
      illness that results in the Advisor&#8217;s being unable to substantially perform its
      duties hereunder for six consecutive months (or for six months out of any
      nine-month period). During a period of Disability, the Advisor shall continue
      to
      receive the advisory fee hereunder. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>9.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Corporate
      Opportunities; Intellectual Property</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Advisor acknowledges that by virtue of its efforts as a Advisor hereunder to
      the
      Company and of Gary M. Post&#8217;s serving as a director, the Advisor may become
      aware of confidential information identified as such in writing by the Company
      relating to the Company&#8217;s business opportunities and potential acquisitions of
      companies and or technologies/compounds (&#8220;Confidential Information&#8221;), and that
      the Advisor will not, during the Term and for a period of 6 months thereafter
      (the &#8220;Restricted Period&#8221;), directly or indirectly use any such Confidential
      Information for its own benefit or for the benefit of any third person other
      than the Company or its affiliates or enter into or negotiate a transaction
      with
      any person that was the subject of the Company&#8217;s business opportunity or
      potential acquisition without the prior written approval of the Company or
      following an express decision by the CEO or the Board not to pursue the specific
      business opportunity or potential acquisition. The foregoing limitation shall
      not apply to the Advisor after the end of the Restricted Period. The
      restrictions set forth in this Section 9 are in addition to any of the fiduciary
      obligations of Gary M. Post to the Company by virtue of his being a director
      of
      the Company.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">4</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)
      Notwithstanding the foregoing, the Company acknowledges that the Advisor may
      pursue its own independent business interests and activities during the
      Restricted Period, including those relating to life sciences and medical
      technologies, which the Company acknowledges are not business opportunities
      of
      the Company and, therefore, which may be pursued by the Advisor on its own
      or in
      association with others independently of the Company during the Restricted
      Period. The Advisor is under no obligation hereunder to identify specific
      potential business opportunities or acquisitions for the Company. However,
      once
      the Advisor informs the Company of a potential opportunity during the Term,
      it
      may not independently pursue that opportunity during the Restricted Period
      without the prior written approval of the Company or following an express
      decision by the CEO or the Board not to pursue the specific business opportunity
      or potential acquisition.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)
      Any
      material or other work which may be subject to copyright or patent, and which
      is
      conceived, derived, made or written by the Advisor in connection with the
      Confidential Information shall be deemed a &#8220;work for hire,&#8221; (and is herein
      referred to as a &#8220;Development&#8221;). As between the Advisor and the Company, Advisor
      acknowledges that all Developments will be the sole and exclusive property
      of
      the Company and shall also be deemed Confidential Information under this
      Agreement. The Advisor further acknowledges the Company may in turn negotiate
      with any third party regarding their respective ownership rights to such
      Developments. The Advisor shall execute such documents as may be necessary
      to
      vest in the Company or any third party, if applicable, all right, title and
      interest in and to the Developments. The Company (or a third party, if
      applicable) will pay all costs and expenses associated with any applications
      and
      the transfer of title to Developments, including paying the Advisor&#8217;s reasonable
      attorneys&#8217; fees for reviewing such documents and instruments presented for
      execution. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)
      Notwithstanding the foregoing, the assignment by the Advisor to the Company
      (or
      a third party, if applicable) of Developments, as well as the right to apply
      for
      and obtain patents and/or registered copyrights on the same, shall be expressly
      limited to those specifically involving the Confidential Information relating
      to
      such projects as mutually agreed upon by the parties hereto, and shall
      specifically not include (i) any right, license or interest of the Company
      to
      general concepts, formats, methods, testing techniques, study designs, computer
      software or other procedures utilized or designed by the Advisor in performing
      its duties hereunder, or any general inventions, discoveries, improvements,
      or
      copyrightable materials relating thereto, nor (ii) any patentable or
      copyrightable materials which can be shown by competent proof not to concern
      the
      subject matter of the Confidential Information, or, which predate this Agreement
      or the Advisor&#8217;s receipt of the Confidential Information, or (iii) any
      intellectual property relating to the Advisor&#8217;s current activities.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(e)
      The
      Advisor agrees that this Section 9 may be enforced by the Company by injunction,
      or other equitable relief, without prejudice to any other rights and remedies
      that the Company may have under this Agreement and without the posting of any
      bond.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>10.</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Legal
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Expenses</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      The
      costs of the Advisor&#8217;s counsel, Adam Eilenberg related to the negotiation,
      preparation and review of this Agreement, in the amount of $2,500, shall be
      paid
      by the Corporation, in the form of shares of Common Stock, based on a price
      equal to 85% of the Market Price, and shall be issued to Adam Eilenberg. Any
      shares issued pursuant to the foregoing sentence shall have the same
      registration rights as those being provided to Advisor hereunder and pursuant
      to
      the Registration Rights Agreement.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>11.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Notices</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All
      notices, claims, certificates, requests, demands and other communications
      hereunder shall be in writing and shall be deemed to have been duly given and
      delivered if personally delivered or if sent by nationally-recognized overnight
      courier, by telecopy, or by registered or certified mail, return receipt
      requested and postage prepaid, addressed as follows:</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">5</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      to the
      Company, to:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">OXIS
      International, Inc. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">323
      Vintage Park Drive, Suite B</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Foster
      City, California 94404</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Attention:
      Chairman of the Board </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">if
      to the
      Advisor, to:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ambient
      Advisors LLC</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Box
      24976</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Los
      Angeles, CA 90024</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Attention:
      Gary M. Post </font></div>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">or
      to
      such other address as the party to whom notice is to be given may have furnished
      to the other party or parties in writing in accordance herewith. Any such notice
      or communication shall be deemed to have been received in the case of personal
      delivery, on the date of such delivery, in the case of nationally-recognized
      overnight courier, on the next business day after the date when sent, in the
      case of telecopy transmission, when received, and in the case of mailing, on
      the
      third business day following that on which the piece of mail containing such
      communication is posted.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>12.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Binding
      Agreement; Benefit</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Subject
      to Section 16, the provisions of this Agreement will be binding upon, and will
      inure to the benefit of, the respective heirs, legal representatives, successors
      and assigns of the parties.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>13.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Governing
      Law</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      Agreement will be governed by, and construed and enforced in accordance with,
      the laws of the State of California (without giving effect to principles of
      conflicts of laws).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>14.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Waiver
      of Breach</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      waiver by either party of a breach of any provision of this Agreement must
      be in
      writing and shall not operate or be construed as a waiver of any other
      breach.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>15.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Entire
      Agreement; Amendments</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      Agreement contains the entire agreement between the parties with respect to
      the
      subject matter hereof and supersedes all prior agreements or understandings
      between the parties with respect thereto. This Agreement may be amended only
      by
      and agreement in writing signed by the parties.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>16.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Headings</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      section headings contained in this Agreement are for reference purposes only
      and
      shall not affect in any way the meaning or interpretation of this
      Agreement.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>17.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Assignment</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      Agreement is personal in its nature and the parties shall not, without the
      consent of the other, assign or transfer this Agreement or any rights or
      obligations hereunder; </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>provided</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>however</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
      that
      the Company may assign this Agreement to any of its subsidiaries.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>18.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Counterparts</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      Agreement may be executed in counterparts, and each such counterpart shall
      be
      deemed to be an original instrument, but both such counterparts together shall
      constitute but one agreement.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>[remainder
      of page left intentionally blank]</strong></font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">6</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>IN
      WITNESS WHEREOF,</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      the
      parties hereto have executed and delivered this Advisory Agreement as of the
      date first written above.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;OXIS
      INTERNATIONAL,
      INC. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;By:
<u>/s/
      Marvin S.
      Hausman, M.D.<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;</u></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt"><u>&#160;</u></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;
</font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Name:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;
Title:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;AMBIENT
      ADVISORS
      LLC</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;By:<u>/s/
      Gary M.
      Post<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;</u></font><u><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></u></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Gary
      M.
      Post </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">7</font>
      <hr style="COLOR: black" align="left" noshade size="2" width="100%">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;

      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
    </div>
  </body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>consultingagreement.htm
<DESCRIPTION>CONSULTING AGREEMENT BETWEEN OXIS INTERNATIONAL, INC. AND JOHN E. REPINE, M.D. DATED NOVEMBER 6, 2006
<TEXT>
<html>
  <head>
    <title>
      Consulting Agreement between OXIS International, Inc. and John E. Repine, M.D.
      dated November 6, 2006
</title>
<!-- Licensed to: OXIS International, Inc.-->
<!-- Document Created using EDGARizer HTML 3.0.4.0 -->
<!-- Copyright 2006 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;</font></div>
    <div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Exhibit
        10.3</strong></font></div>
      <div>&#160;&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>CONSULTING
      AGREEMENT </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">dated
      as
      of November 6, 2006, between Oxis International, Inc., a Delaware corporation
      (the &#8220;Company&#8221;), and John E. Repine, M.D. (the &#8220;Consultant&#8221;).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company desires to retain the Consultant to perform consulting services in
      the
      field of antioxidant and inflammation research for the Company, and the
      Consultant desires to perform such consulting services for the Company, in
      each
      case, upon the terms and conditions hereinafter set forth. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>NOW,
      THEREFORE,</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      in
      consideration of the mutual covenants and obligations hereinafter set forth,
      the
      parties agree as follows:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>1.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Retention
      of Consultant</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company hereby retains the Consultant as a consultant, and the Consultant hereby
      accepts such retention by the Company, upon the terms and conditions hereinafter
      set forth. The Consultant shall perform all such services as an independent
      contractor to the Company and not as an employee, agent or representative of
      the
      Company.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Term</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      retention of the Consultant hereunder shall be for a period commencing as of
      October 15, 2006 (the &#8220;Commencement Date&#8221;) and ending on October 15, 2009 or
      such earlier date provided in this Section 2. This Agreement shall automatically
      terminate prior to such date upon the first to occur of (i) the death or
      disability of the Consultant, (ii) the resignation by the Consultant following
      the delivery by him to the Company of ten days&#8217; advance written notice of such
      resignation or (iii) termination by the Company following the delivery to the
      Consultant of 60 days&#8217; advance written notice from the Company&#8217;s Board of
      Directors of its intention to terminate the Agreement. The period commencing
      on
      the Commencement Date and ending on the date of termination of the Consultant&#8217;s
      retention hereunder shall be called the &#8220;Term&#8221;. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Duties</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During
      the Term, the Consultant shall advise the Company concerning matters of
      antioxidant and inflammation research and potential acquisitions (including
      products/compounds/intellectual property as well as companies), and product
      research and development. The Consultant shall also advise the Company regarding
      the development and establishment of reference labs for oxidative stress and
      inflammatory reactions. For each such matter, the Consultant will initiate
      his
      advisory services only after being requested to do so by the Chief Executive
      Officer of the Company (the &#8220;CEO&#8221;). At the outset of each project, the CEO will
      define its scope and timing. The Consultant shall report directly to, and shall
      reasonably update, the CEO or his designee on the status of each project, and
      shall reasonably coordinate his efforts with members of management and other
      consultants to the Company. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>4.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Time
      to be Devoted to Services</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During
      the Term, the Consultant shall not be required to devote any specified amount
      of
      time to the provisions of services hereunder and shall only be required to
      devote such reasonable amount of time to the business of the Company as the
      Consultant shall reasonably determine to be necessary to fulfill his duties
      hereunder.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>5.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Compensation</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company shall pay to the Consultant a consulting fee of $36,000 per annum.
      The
      consulting fee initially will be payable quarterly in advance in the form of
      the
      Company&#8217;s common stock (&#8220;Common Stock&#8221;), at a price equal to 85% of the &#8220;Market
      Price&#8221; for the Company&#8217;s common stock, which shall equal the average of the
      closing prices for the five trading days prior to the date that the issuance
      is
      authorized by the Board of Directors. In lieu of receiving Common Stock for
      such
      payments, the Consultant may elect to receive that number of ten year Warrants
      (with cashless exercise provisions) equal to 1.5 times the number of shares
      of
      Common Stock that would otherwise be received, at an exercise price equal to
      the
      Market Price. The first installment, representing $9,000 of the annual
      consulting fee, and payable at the Consultant&#8217;s election either in the shares of
      Common Stock of form of warrants described in the foregoing sentence, will
      be
      paid promptly after the determination of the Market Price, and thereafter,
      will
      be paid on the dates that are three months, six months and nine months from
      the
      date hereof, and quarterly thereafter for the duration of the Term.
      Notwithstanding the foregoing, once the Company has raised at least $2.5 million
      in one or more financings (equity, debt or convertible debt, in addition to
      the
      financing closed on October 27, 2006) or in a strategic transaction (a
&#8220;Qualifying Financing&#8221;), the consultant may elect, at any time, in lieu of
      receiving a quarterly issuance of stock (or warrants in lieu thereof), to
      receive his consulting fee in cash, payable quarterly. All shares of Common
      Stock issuable to the Consultant under this Agreement (if not otherwise
      registered pursuant to an existing stock option plan covered by a registration
      statement on Form S-8), or upon the exercise of the warrants to be issued in
      lieu thereof, shall have the benefit of piggyback registration rights, pursuant
      to a Registration Rights Agreement to be executed by the Company and the
      Consultant (the &#8220;Registration Rights Agreement&#8221;); provided, however, that the
      failure to execute such a Registration Rights Agreement shall not limit the
      Consultant&#8217;s piggyback registration rights hereunder.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>6.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Bonus
      Awards</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During
      the Term, the Consultant shall be eligible to annual and special bonuses based
      upon the attainment of agreed upon goals and milestones as determined by the
      CEO, relating to special contributions made by the Consultant to the Company&#8217;s
      business, product development and intellectual property. Each bonus payable
      hereunder shall be paid in cash, although at the Consultant&#8217;s sole option, such
      bonus may be paid in stock (or in the form of ten year warrants with cashless
      exercise provisions, with 1.5 times the number of warrants to be issued in
      lieu
      of the number of shares of Common Stock), based upon the average of the closing
      bid and asked prices for the 5 trading days immediately prior to the awarding
      to
      the Consultant of the particular bonus (which shall also be the exercise price
      of the warrants, if the Consultant elects to receive warrants). The Consultant
      shall make his election no more than ten (10) days following notification by
      the
      Company of a bonus award, and the failure to make timely election shall mean
      that the Consultant shall receive the bonus in the form of cash.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>7.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Stock
      Options</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
      soon
      as practicable following execution of this Agreement, the Consultant shall
      be
      granted ten-year options for the purchase of up to 200,000 shares (the &#8220;Initial
      Option Grant&#8221;) of Common Stock under the Company&#8217;s existing stock option plan
      (the &#8220;Plan&#8221;). The terms of the grant, including the vesting schedule and
      exercise price of the Initial Option Grant, shall be as set forth in a separate
      option agreement executed by and between the parties and will provide, among
      other things, (i) for cashless exercise provisions and (ii) for the vesting
      of
      100,000 options in four equal quarterly installments commencing on the date
      that
      is three months from the Commencement Date and every three months thereafter,
      (iii) for the vesting of the remaining 100,000 options in eight quarterly
      installments over the subsequent two years and (iv) for an exercise price equal
      to the average of the closing bid and asked prices for the Common Stock on
      the
      trading day immediately prior to the date hereof. Subsequent stock option grants
      will be determined annually by the Company&#8217;s Board of Directors (the &#8220;Board&#8221;)
      and its Compensation Committee. During the Term, the Consultant will be deemed
      to be an employee of the Company for the purpose of his existing stock options,
      including those granted pursuant to Sections 7 and 8 hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">2</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>8.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Sign
      On Bonus</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
      a
      sign-on bonus and as soon as practicable following execution of this Agreement,
      the Company shall issue to the Consultant an additional ten-year option under
      the Plan for the purchase of up to 200,000 shares (the &#8220;Sign On Option Grant&#8221;).
      The terms of the grant, including the vesting schedule and exercise price of
      the
      Sign On Option Grant, shall be as set forth in a separate option agreement
      executed by and between the parties and will provide, among other things, (i)
      for cashless exercise provisions, and (ii) for an exercise price equal to the
      average of the closing bid and asked prices for the Common Stock on the trading
      day immediately prior to the Commencement Date. The options issued under this
      Section 8 will vest monthly in six equal installments, commencing on the date
      that is 30 days after the Commencement Date, through the 180</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>th</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      day
      after the Commencement Date. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>9.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Business
      Expenses: Benefits</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
      The
      Company shall reimburse the Consultant in cash, in accordance with its practice
      from time to time, for all reasonable and necessary travel, entertainment and
      other expenses and other disbursements incurred by the Consultant for or on
      behalf of the Company in the performance of the Consultant&#8217;s duties hereunder.
      The Consultant shall provide such appropriate documentation of expenses and
      disbursements as may from time to time be required by the Company.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company shall have no obligation to provide any benefits to Consultant,
      including without limitation, any health, life or disability
      benefits.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>10.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Indemnification;
      Insurance</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company will indemnify the Consultant for his actions in the capacity as a
      consultant hereunder (other than resulting from his gross negligence or willful
      misconduct) and as a director of the Company and any of its subsidiaries to
      the
      full extent permitted by law and as provided in the Company&#8217;s Certificate of
      Incorporation and by-laws. The Company also will include the Consultant on
      its
      existing Directors and Officers liability insurance policy, which the Company
      represents is for a customary amount for similar public companies in the life
      sciences industry.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>11.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Additional
      Payments and Stock Issuances</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company agrees whenever it makes any payment of cash to the Consultant hereunder
      (other than for the reimbursement of expenses), it will simultaneously pay
      to
      University Physicians Inc., 13611 East Colfax Avenue, Aurora, CO 80011 (&#8220;UPI&#8221;) a
      cash payment equal to 13.5% of the cash paid to the Consultant, and that
      whenever the Company grants a stock option to the Consultant, it will
      simultaneously grant to UPI an award for 10% of the number of options awarded
      to
      the Consultant, at the same exercise price and subject to the same rights,
      terms
      and conditions as the option grant awarded to Consultant (including, without
      limitation, exercise price, vesting provisions, cashless exercise rights and
      piggyback registration rights). UPI shall be a third party beneficiary of this
      Section 11. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">3</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>12.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Termination
      Payments</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      the
      Company terminates this Agreement pursuant to Section 2(iii) without Cause
      after
      the six month anniversary of the date of this Consulting Agreement, Consultant
      shall receive an amount equal to twelve (12) months of the consulting fee for
      the then current Term in a lump sum payment, and all outstanding stock options
      shall become fully vested and the warrants vested as of the date of termination
      and the stock options shall remain exercisable through their respective
      expiration dates. If the Company terminates this Agreement pursuant to Section
      2(iii) without Cause prior the six month anniversary of the date of this
      Consulting Agreement, Consultant shall be paid any expenses due to him and
      all
      vested stock options and warrants shall remain exercisable through their
      respective expiration dates. &#8220;Cause&#8221; shall mean means (i) willful malfeasance or
      willful misconduct by the Consultant in connection with the performance of
      his
      duties hereunder; (ii) the Consultant&#8217;s gross negligence in performing any of
      his duties under this Agreement; (iii) the Consultant&#8217;s conviction of, or entry
      of a plea of guilty to, or entry of a plea of nolo contendere with respect
      to,
      any felony; (iv) the Consultant&#8217;s habitual drunkenness or use or possession of
      illegal drugs while performing his duties under this Agreement or excessive
      absenteeism not related to illness; (v) the Consultant&#8217;s material breach of any
      written policy applicable to all employees and consultants adopted by the
      Corporation; or (vi) material breach by the Consultant of any of his agreements
      in this Agreement having a material detrimental impact on the Corporation after
      written notice and a reasonable opportunity to cure of not less than 30
      days.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      the
      Company terminates this Agreement pursuant to Section 2(iii) for Cause (other
      than pursuant to Section 8(a)(vi), for which the notice requirement is 30 days),
      the Company will only be required to give ten (10) days&#8217; prior notice, and in
      such event the Consultant shall not be entitled to any further payments of
      his
      consulting fee hereunder, and any unexercised stock options shall
      expire.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      the
      Consultant resigns pursuant to Section 2(ii), for whatever reason, or dies
      or
      becomes disabled, the Consultant (or his estate) shall not be entitled to any
      further payments of his consulting fee hereunder, all unvested stock options
      and
      warrants shall expire, and all vested stock options and warrants shall remain
      exercisable until their respective expiration dates. &#8220;Disability&#8221; shall mean the
      Consultant&#8217;s incapacity due to physical or mental illness that results in his
      being unable to substantially perform his duties hereunder for six consecutive
      months (or for six months out of any nine-month period). During a period of
      Disability, the Consultant shall continue to receive his consulting fee
      hereunder. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>13.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Corporate
      Opportunities; Intellectual Property</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Consultant acknowledges that by virtue of his efforts as a consultant hereunder
      to the Company and as a director, he may become aware of confidential
      information identified as such in writing by the Company relating to the
      Company&#8217;s business opportunities and potential acquisitions of companies and or
      technologies/compounds (&#8220;Confidential Information&#8221;), and that he will not,
      during the Term and for a period of 6 months thereafter (the &#8220;Restricted
      Period&#8221;), directly or indirectly use any such Confidential Information for his
      own benefit or for the benefit of any third person other than the Company or
      its
      affiliates or enter into or negotiate a transaction with any person that was
      the
      subject of the Company&#8217;s business opportunity or potential acquisition without
      the prior written approval of the Company or following an express decision
      by
      the CEO or the Board not to pursue the specific business opportunity or
      potential acquisition. The foregoing limitation shall not apply to the
      Consultant after the end of the Restricted Period. The restrictions set forth
      in
      this Section 12 are in addition to any of Consultant&#8217;s fiduciary obligations to
      the Company by virtue of his being a director of the Company.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">4</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)
      Notwithstanding the foregoing, the Company acknowledges that the Consultant
      may
      pursue his own independent business interests and activities during the
      Restricted Period, including those relating to life sciences and medical
      technologies. Such business interests and activities include, without
      limitation, those identified on Schedule A annexed hereto, which the Company
      acknowledges are not business opportunities of the Company and, therefore,
      which
      may be pursued by the Consultant on his own or in association with others
      independently of the Company during the Restricted Period. The Consultant is
      under no obligation hereunder to identify specific potential business
      opportunities or acquisitions for the Company. However, once the Consultant
      informs the Company of a potential opportunity during the Term (other than
      those
      set forth on Schedule A), he may not independently pursue that opportunity
      during the Restricted Period without the prior written approval of the Company
      or following an express decision by the CEO or the Board not to pursue the
      specific business opportunity or potential acquisition.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)
      Any
      material or other work which may be subject to copyright or patent, and which
      is
      conceived, derived, made or written by the Consultant in connection with the
      Confidential Information shall be deemed a &#8220;work for hire,&#8221; (and is herein
      referred to as a &#8220;Development&#8221;). As between the Consultant and the Company,
      Consultant acknowledges that all Developments will be the sole and exclusive
      property of the Company and shall also be deemed Confidential Information under
      this Agreement. The Consultant further acknowledges the Company may in turn
      negotiate with any third party regarding their respective ownership rights
      to
      such Developments. The Consultant shall execute such documents as may be
      necessary to vest in the Company or any third party, if applicable, all right,
      title and interest in and to the Developments. The Company (or a third party,
      if
      applicable) will pay all costs and expenses associated with any applications and
      the transfer of title to Developments, including paying the Consultant&#8217;s
      reasonable attorneys&#8217; fees for reviewing such documents and instruments
      presented for execution. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)
      Notwithstanding the foregoing, the assignment by the Consultant to the Company
      (or a third party, if applicable) of Developments, as well as the right to
      apply
      for and obtain patents and/or registered copyrights on the same, shall be
      expressly limited to those specifically involving the Confidential Information
      relating to such projects as mutually agreed upon by the parties hereto, and
      shall specifically not include (i) any right, license or interest of the Company
      to general concepts, formats, methods, testing techniques, study designs,
      computer software or other procedures utilized or designed by the Consultant
      in
      performing his duties hereunder, or any general inventions, discoveries,
      improvements, or copyrightable materials relating thereto, nor (ii) any
      patentable or copyrightable materials which can be shown by competent proof
      not
      to concern the subject matter of the Confidential Information, or, which predate
      this Agreement or the Consultant&#8217;s receipt of the Confidential Information, or
      (iii) any intellectual property relating to the Consultant&#8217;s current activities
      identified on Schedule A. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(e)
      The
      Consultant agrees that this Section 12 may be enforced by the Company by
      injunction, or other equitable relief, without prejudice to any other rights
      and
      remedies that the Company may have under this Agreement and without the posting
      of any bond.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>14.</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Legal
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Expenses</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      The
      costs of the Consultant&#8217;s counsel, Adam Eilenberg, related to the negotiation,
      preparation and review of this Agreement, up to $2,500, shall be paid by the
      Corporation, in the form of shares of Common Stock, based on a price equal
      to
      85% of the Market Price and shall be issued to Adam Eilenberg. Any shares issued
      pursuant to the foregoing sentence shall have the same registration rights
      as
      those being provided to Consultant hereunder and pursuant to the Registration
      Rights Agreement.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>15.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Notices</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All
      notices, claims, certificates, requests, demands and other communications
      hereunder shall be in writing and shall be deemed to have been duly given and
      delivered if personally delivered or if sent by nationally-recognized overnight
      courier, by telecopy, or by registered or certified mail, return receipt
      requested and postage prepaid, addressed as follows:</font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">5</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      to the
      Company, to:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">OXIS
      International, Inc. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">323
      Vintage Park Drive, Suite B</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Foster
      City, California 94404</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Attention:
      Chairman of the Board </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">if
      to the
      Consultant, to:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">John
      E.
      Repine, M.D. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">c/o
      Webb-Waring Institute</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Box
      c322</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4200
      E.
      Ninth Avenue, Denver, CO 80262</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">with
      a
      copy to:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">John
      E.
      Repine, M.D. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">70
      Cherry
      Hills Farm Drive</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Englewood,
      CO 80113 </font></div>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">or
      to
      such other address as the party to whom notice is to be given may have furnished
      to the other party or parties in writing in accordance herewith. Any such notice
      or communication shall be deemed to have been received in the case of personal
      delivery, on the date of such delivery, in the case of nationally-recognized
      overnight courier, on the next business day after the date when sent, in the
      case of telecopy transmission, when received, and in the case of mailing, on
      the
      third business day following that on which the piece of mail containing such
      communication is posted.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>16.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Binding
      Agreement; Benefit</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Subject
      to Section 20, the provisions of this Agreement will be binding upon, and will
      inure to the benefit of, the respective heirs, legal representatives, successors
      and assigns of the parties.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>17.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Governing
      Law</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      Agreement will be governed by, and construed and enforced in accordance with,
      the laws of the State of California (without giving effect to principles of
      conflicts of laws).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>18.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Waiver
      of Breach</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      waiver by either party of a breach of any provision of this Agreement must
      be in
      writing and shall not operate or be construed as a waiver of any other
      breach.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>19.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Entire
      Agreement; Amendments</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      Agreement contains the entire agreement between the parties with respect to
      the
      subject matter hereof and supersedes all prior agreements or understandings
      between the parties with respect thereto. This Agreement may be amended only
      by
      and agreement in writing signed by the parties.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>20.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Headings</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      section headings contained in this Agreement are for reference purposes only
      and
      shall not affect in any way the meaning or interpretation of this
      Agreement.</font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">6</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>21.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Assignment</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      Agreement is personal in its nature and the parties shall not, without the
      consent of the other, assign or transfer this Agreement or any rights or
      obligations hereunder; </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>provided</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>however</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
      that
      the Company may assign this Agreement to any of its subsidiaries.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>22.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Counterparts</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      Agreement may be executed in counterparts, and each such counterpart shall
      be
      deemed to be an original instrument, but both such counterparts together shall
      constitute but one agreement.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>[remainder
      of page left intentionally blank]</strong></font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">7</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>IN
      WITNESS WHEREOF,</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      the
      parties hereto have executed and delivered this Consulting Agreement as of
      the
      date first written above.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;OXIS
      INTERNATIONAL,
      INC. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;By:
<u>/s/
      Marvin S.
      Hausman, M.D.</u><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Name:&#160;
      Marvin S. Hausman, M.D.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>Title:&#160;
President
      &amp; Chief Executive Officer</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#16
0;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>&#160;/s/
      John E. Repine, M.D.&#160;&#160;&#160;&#160;</u></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;John
      E. Repine, M.D. </font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">8</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SCHEDULE
      A</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>EXISTING
      BUSINESS INTERESTS AND ACTIVITIES OF THE CONSULTANT</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.
      Use of
      Near-Infrared Spectrometry technique to non-invasively measure factors that
      predict and reflect changes in Diabetes, ARDS and other disorders.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.
      Development of intellectual property of ways to treat age-related macular
      degeneration.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.
      Development of CD40 T Cell diagnostics and therapeutics</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.
      Development of biomarker microarrays to predict the acute respiratory distress
      syndrome (ARDS) and of proprietary elastase inhibitors to prevent
      ARDS.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.
      Development of novel glucose molecules for nutritional and therapeutic
      purposes.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">9</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
      </font>
      <div>
        <hr style="COLOR: black" align="left" noshade size="2" width="100%">
      </div>
    </div>
  </body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>oxislogo.jpg
<DESCRIPTION>OXIS LOGO
<TEXT>
begin 644 oxislogo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0`\17AI9@``24DJ``@````!`#$!`@`9
M````&@````````!%1$=!4FEZ97(@4V]F='=A<F4@4W5I=&4`NO_;`$,``@$!
M`0$!`@$!`0("`@("!`,"`@("!00$`P0&!08&!@4&!@8'"0@&!PD'!@8("P@)
M"@H*"@H&"`L,"PH,"0H*"O_;`$,!`@("`@("!0,#!0H'!@<*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"O_``!$(
M`%L!:0,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)
M"@O_Q`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1
MH0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-4
M55976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::G
MJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U
M]O?X^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"
M`0($!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2
M\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D
M969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2U
MMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,
M`P$``A$#$0`_`/W\HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBO`_VP?V]?A]^S#:/X9TJ.+7?%\L>8=&CEQ':!AE9+EAR@P00@^9N/N@[@!>
MQ[-XT\=^#?AQX>G\6>//$UEI&FV_^MO+^X6-`3T4$]6/91DD\`&OD7XX_P#!
M7[P?H<D^B_`7P3)K4R$JFM:SN@M<_P!Y(1B20?[QC/L:^+/C+\>/BM\?O%#>
M*/B?XKN-1GW'[+:YVV]JI_@BB'RH.G09.,DD\U]"?!/]F;X*?LV>$--^/_[;
MUS_IFH2C_A$?AQ%;&YOM3F./+3[*F7N)6)&(0-JY!E(!*K482E+E2NR.8E\*
M^-/^"E?[7]K)X@TGQM=>&?#&QWEUH2C2-/AB7)9A*@\V50,Y(+XP<D8->B:!
M_P`$DK[Q5#%JWQA_:6U35Y9E$CQV%L74$\Y6:>1]X(/!V#K79V?P'^.?[:=W
M;ZS^U5ILG@;X8V[I)I'P=TN\VW.IHA!C?6)XB!M&`PM(CM7Y0Y+)S]-Z9IFG
M:)IMOH^D6,5K:6D"0VMM!&$CAC50JHJCA5````X`%54A&G97N^MME\^OY>8)
M7/D6[_X(W?!=[9UL?BMXHCE*_(\J6SJ#[J(U)_,5YW\0/V!OVR/V<;*7Q/\`
ML\_&C5-:L;--YLM'O9[*[V@'.+?>R3`#^$,6;H$/2OT&HJ+LKE1^;/P4_P""
ML'QV\!:A'I/QBTVW\5Z:KA)I'A6UOX@./E=`$<CN'3)(^\.37VYX5^(?PO\`
MVQ?@]<7'PV^(VL6=I>-&EU=:%J#6.IZ=(KK)Y;,N6B8[=IZAE9L$@YKX1_X*
MI_!71OAC^T#!XP\-6*6UGXNL&O9XHQA5O$<K.0.P;,;GU9VKR3]F?]H7Q;^S
M9\5;#X@^&[B1[82+%K.G*^%OK0L-\9SQNQRK?PL`?4$:(3:=F??OQ`_8/^*U
MSI\DGPL_;C^*=E=K&3'%K_BB>YBD?L"T31%![X8CK@]*^%/B#\9?VPOA=XUU
M+X?>-?COX\M-5TFZ:WO(&\7WA`8=&!\W#*P(8$<$$'H:_73P[K^D^*_#UAXI
MT&[6>PU*RBNK*=1Q)#(@=&_%2#^-?(/_``5@_9@'BKPK#^T=X/T\G4=%B6W\
M11Q+S-9[L)-@=3&S8)_N-D\1T(J2TT/C:P_:6_:<U&_@T^+]H[QNCSS+&KR^
M,;Q44L<98^;P.>37Z$^"OV$O'EC:1/\`$']MOXMZE<A5,JZ3XKFM(BW<8=I6
M([=0>_%?EM7ZC_\`!-O]IO\`X7M\&$\(>)=0\SQ)X32.TO=[?/=6N,03\]3@
M%&/)W)DXWBFT);GT!X<T9?#?AZP\.IJ=[>BPLHK87FI7)FN+C8@7S)9#R\C8
MRS'J23WIGBOP^OBOPU?>&GUC4-/6^MG@-]I5V8+F#<,;XI!RCCLPZ&M"O.OV
MC/VG_A9^S+X3_P"$B^(&K9NYT;^S-&MB&N;YQV5>R@XRYPH]22`9+/"?VL?V
M</%'P8^#FN?%;PI^VO\`%2QDTNW$D-GK?C*::*YD+`+"A0QL&;.T?>YY/&:^
M*M'_`&BOVL/$6J0:'H'QU^(5[>W4@CMK2T\47TDDKGHJJLA+'V%>GZUXB_:I
M_P""G?Q1&DZ/8&TT&QGW):K(RZ;I$9X#ROC][*1GG!=N=JJH('W#^RU^Q?\`
M"?\`9;T99=`M/[4\0S1;;_Q)>PCSGXY2)>1#'G^%22>-S-@8>Q%KO0\#^`W[
M&?[<OC2RA\0?&K]K#QOX6M9%#+I=MXJN[B^(_P!O]]Y<7YN>Q45[>O[%$`L!
M:M^U5\:FEV8-S_PL*4-G^]C9M_#%>VT4BDD?FA^VYI7[2?[)GCK3=#TO]KKQ
MYJ^G:S9/<6;S^*+R.XAV,%99`LI!&2"&&,\C`VY/BO\`PU%^TS_T<5X[_P#"
MNO?_`([79?\`!0?XTQ_&O]IS6]0TR\$NEZ&1I&ELIRK)"6\QQC@AI6E8'NI7
MGI7#_L\?"+4/CM\:/#_PML1($U34%6]FC',-LOSS2>F1&K$>IP.]49O<^POV
M1/V8/VG/C3X"LOBI\7_VM_B3H^FZH@ETO2],\4W0N9H#]V9I)'98PPY4;&RI
M#9&<%GQR_;6T/]CVUU#X)?`_Q]XA\>>)4O&.K:]XXUE]132Y`H1H4.%WN"N2
MH^1&)SD[E'TC^U3XUN_@7^RQXH\3>!H19S:1H:VND_9T.+4NR6\;*!T\O>&'
M8;>>*_'V:::YF:XN)7>1W+.[MDL3U))ZD^M"5RGH?1/PRN/V[/V[O$MWI6E?
M%/69+"!@VJ7DVI/9Z;:[NBLD`"LQYPBJ6QDX`R:][\/_`/!'CPG=6:2_$GXZ
M:[J-YLP6L+2.)$[[1YID)'Y9ZX'2O1_^"7=YX3N?V/\`1(?#8C%S!J%ZFMA2
M"WVHSLP+X`Y\EH<?[.T<XS7T-2N-15CY)E_X)9S>&T^T_";]JGQKH-XH7RYV
ME+C*YQ_J7B(]N>/>O*/C?XX_X*0?L2B%O$/Q>?7O#]Y+Y5IK<MK'>Q^9R1'(
MT\9DBD*@D*25;G!;:<?H;7*?''X8Z7\9?A'XA^&.K6Z/'J^ERPQ%@/W<V-T4
M@]TD",/=:0<O8_,CX>^,OC%^W-^TWX-\)?%[Q?<ZU!+JRM+:.B16\%HG[ZX"
M11J$4F*-ANQDX4$G`K[F_P"';7[+G_0G?HG_`,37SM_P1S^%O]J>/O$_Q@OK
M8&+2-/CTVP=UX,T[;Y&4^JI&%/M-^7Z"TV**NM0HHHI%A1110`5S_P`5]6U'
MP_\`"WQ+KVCW1@N['0+RXM9E`)CD2!V5AG@X(!YKH*Y?XW_\D8\7_P#8K7__
M`*3254%>:$]C\\/@W\2/VU?B;\,M!\=ZA^W+XIM9M7TN&ZEMX?#^F,L;.H)4
M$P9(YKL[:+]L>?&[]OKQ>OT\.Z7_`/&*X#]EB_V_L_>#4S]WP[:]_P#IF*]6
MT[40P`+<UV5:TXU9))63?V5_D8Q5XIE>WT+]L.;&?^"@'C'GT\.:7_\`&*T+
M7P5^U]<8S_P4&\9C/IX;TKC_`,@5JZ=J&,?-6WI^H8P"W'UK#ZS5\O\`P&/^
M0^5'/VWPQ_:YGQG_`(*&>-/?_BFM*_\`C%:%K\&?VM+C&[_@HGXV'KCPSI7_
M`,8KK=/U#."'K;T_4.A#<_6J^L5+:6_\!C_D'*CB;;]GW]J^<@'_`(*->.!]
M/#&D_P#QBM&U_9C_`&JKCK_P4@\=`^@\+Z3_`/&*]#TS5.@+<?6OFS]LK_@K
MA\,/V3O%<OPP\*^$9O&'BFV16U"VBOQ;6M@6`(227:Y:3:0Q15X!`+`\"Z,L
M57GR4XIO_#'_`""7LXJ[?XL]<_9Q/QQ^'G[87B#X%_$G]HO6O'^EI\-+#7K.
M76M,M+9[:XFU"ZMV4?9XUR-MNO7/WC7TM7YA?L6_\%9OAQ\8/VYV\:?&?PRO
M@MO$G@FQ\*:7*E^;JU^U1W]Q<(TLA1#"'^T[`2"H*9+`-Q^C?Q:^(^A_"'X9
M:[\3_$DBK9Z%I<UY,&D"[]BDJ@)X!9L*/=A1C:-6E52G&S:7]::#I2C*.C/#
MO^"@O[;*?LW^&D\`_#^YCD\9:Q;EX9&`==,MSD>>P/5R<A%(QD%CP`K?F'K^
MOW5_=77B3Q/K,DTTTC37M]?7!9G8G)=W8Y))ZDFH?BM\?/%_QR^(6K>/8H3K
M.JZM>-+=7[L4LX.RHKG)944*JJF<*H&15[X!?LV:W^T)\9/#_P`/=9U1M1O-
M4OU4IY>VULHE!>6419^8I&KMEB2<8XK-45#6H[>77[NGS_$3FY/0]<_83^`?
M[0/QM\76WQ)^$GPYT^'1K5B=.\=>,K=SIMM.K8,]O:C#ZA)&0VP96)9`"S';
MM/Z*?`_]D3X??"'Q#/\`$WQ#JE_XT\?W\>W4O'OBIEFOF7O%``!'9P#)`BA5
M1C`;=@&O1?!_A/0?`?A73O!/A73DM=-TFRCM+&WC'$<4:A5'OP.3W/-:53*L
M[<L%9?B_5_\`#+R+C!+<****Q+"BB@D*"S'`'4F@#\^O^"S.N65Q\1O!7AN-
M\W-IHES<RKGHDTRJA_.!_P`J^,*]<_;B^-5I\>/VD]?\8Z/=^=I5K(NG:/(#
MD-;PC;O'^R[^9(/9Z\HLK.[U&\BT^PMVFGGE6.&*-<L[L0`H'<DG&*M;&>[/
MUN_8$O-2OOV/?`L^JEO-72WC7<2?W:3RI'U`_@5?_K]:]:U/3=/UK3;C1]6L
MH[BTNX'AN;>9=R2QL"K*P/4$$@CWKGO@KX`7X5_"+PS\.1L+:+HEM:3-'T>5
M(U$C_P#`GW'\:ZBH+6B/R`_;&_9RU']F;XUZAX)6.1]'NR;SP]=OD^;:.QVH
M6/5T.4;U*[L`,*S?V6_CYK/[-WQGTKXE:<9)+6-_L^LV<;8^U6;D"1/J,!U_
MVD7-?HW_`,%"/V==*^/7P$O[Z,V\&M^%X9=2TB\N'5`%5<S0L[$!5=%ZD@!E
M0DX!K\H:I:D-69^F?[5/_!3'X8_";P['I/P;O[/Q1XBU"S2:VDADW6=BDB!D
M>5E/S-@@B($'^\5X!^?/V>OV,/C?^VSXP;XY?M#^)=3M=#O9!(]_=#%WJ29R
M$MD(VQ0@<!MNP#`16&<<_P#\$ROAY\!_B5\=)=%^+UD;S48+07/AK3;EE^R7
M4J9:42(1F1U7#JN=I"N2#@5^H4<<<,:Q1(JHJ@*JC``]*6PTN;5F)\./AKX'
M^$GA&U\"_#OPY;Z7I=FN(K:W7J>[LQY=SW9B2>YK=HHI%A7EO[9GQN7X!?L[
MZ_XYM;P1:G+!]AT3#88WDP*HR^Z#=)CTC->I5^=G_!7?XW?\)/\`%#2O@AI%
M[FT\-VXNM413P;R905!]TA*D?]=F%"W$W9'Q^26)9CSU)-?=_P#P1Z^"'DV>
MO_M`ZS9C=,?[(T1G7HHVR7$@SZGRT!']V0=S7PUH6B:IXEUNS\.:'9-<7NH7
M<=M9P)UEE=@J*/<L0/QK]G?@;\*]+^"?PDT#X6Z05,>C:<D,LJ#B:8_-+)_P
M*1G;_@55(E*[+7Q9^'&B?%_X;:W\,?$;,MGK6GR6TLL8RT1(^61?4JP5@.F5
MK\?_`(Z_`WQ]^SU\0KOX=_$'2VAN(&WVMT@/DWL!)"S1-_$IQ]005(!!%?M%
M7%?'/X`?##]HKP:_@OXFZ"+J)26L[R$A+BRD(QYD4F/E/3(Y5L88$<4AM7/R
MJ_9G_:D^)'[+GC0^)?!%PEQ9705-7T6Z<^1>Q@\9Q]UQD[7'*Y/!!93^G_[.
M'[5GPD_:=\-?VMX"UCRM1@C!U/0KPA;JS8^J_P`:9Z.N5/3@Y4?G#^UA^P[\
M4OV7=4?4[F%M9\+32[;+Q#:0D*F3Q'.HSY3_`(E6_A).0/*/!WC/Q7\/O$=K
MXN\$^(+K2]2LI-]M>V<I1T/IGN#T(/!'!!%.R9-W$_<"BOD?]CS_`(*=>&/B
MBUI\.OCR]MHOB*1EBM-80;++4&/`#?\`/"4_]\,<X*Y"5]<5)::9@^`OAGX`
M^%NF7.C?#SPG9Z1:WEZ]W=0646U9)W"AI#[D*H^@`K=VC_(I:*!A1110`444
M4`%<O\;_`/DC'B__`+%:_P#_`$FDKJ*Y?XW_`/)&/%__`&*U_P#^DTE73^->
MHGL?F7^S)?;/@1X0CW8QH%M_Z+%>HZ=J/3YN:\7_`&<+W9\$/"B;NFA6X_\`
M'!7I>GZAT!;Z&MJ_\>7J_P`S*'PH[O3M1#``MS6[IVH8Q\U<)IVH]/FYK>T[
M40P`+<UBU<H[C3]0Q@%N/K6[I^H9P0]</IVH8Q\U<)\4?VY_V;O@B)+?Q5\1
MK:[OXL@Z5HI^UW&X9^5@GRQGCH[+^M.G3J5)6@FWY";4=SZ.T_4.A#<_6OPM
M_:!7Q,OQW\:#QF7.K_\`"5:A_:)ESDS?:'WGGWS^%?JEH/C7]IOXZV*7O@FX
MT+X=Z'*!B_N'BUG5W4@.,11M]FMR59>&:8C.=O:N%^,G_!)/X4_&//B.W^+_
M`(HMO%-Q(7U/Q'K+IJ!OV(4;I8OW0&T*%41E`!P0<#'K9=7I8*I+VCW[:V^[
M]+F-6$JB]T_+A59FVJ"23@`=2:_6[]L[]GCQQIO[&&B?$']IGXQ^)O&7B:ZF
MTN%-%N9?L>D:4QB+L@LHB%GE784,TYD9CR`F>/!/AI^S9^Q[_P`$\OVE[KQ+
M^US\09/%T'ASP=9^(?"^G0Z6(&O]2DO+B%85M?-?SS&+<."SK&"V7&`,^O\`
MQ`MOV\?^"@OPLU[]IKQMIR^!_AKH=A)J'@SX?!&:YUA$(+7<[':3MA,C(Y`#
M%0(XP',C=695W6@I4W:*ZO2]^BZ^OXD4H\MT]^Q\K)''#&(8D5$4855&`!Z8
MK['_`."./@.UUCXJ^*_B'<P*[Z'HT%K;E@/W;W4C'</?;;N,^C$=Z^.:^[_^
M"+^JZ?\`8OB!H9E471ETZ<1GJT>+A<CUP<9]-P]:^=9U)>\?<M%%%2:!1110
M`5\T_P#!2C]JFT^"/PHE^&OA;45'BCQ5:O!&L;?/963`I+.<<J6Y1.G)9A]P
MBO3_`-IK]IKP!^S#X`E\8>,+H37LP9-&T:*0":^F`X4?W4'!9SPH]254_DI\
M5_BEXR^-'C_4OB3X\U(W.I:G.7E*Y"1(.%B0?PHJX4#T'))R2TKDR=CG:^MO
M^"7'[*-[\1/'\7Q]\9:6RZ!X<N-VC"9,"^OU/#+GJD1^8G^_L`SM8#"_8G_X
M)Z^*_P!H&\M/B'\2K>XTGP6CB2,E2D^K8(^2+H4C/.9?P7)R5_2WP[X=T+PC
MH5IX8\,:3;V.GV-NL-G9VT82.&-1@*`.U#8DKZEZN3^,?QL^&_P%\&S>.?B;
MXBCL+.,E88_O37,F,B.).KL?0<#J2`":\U_:U_;Q^%_[,5E+H%NZ:YXMDBS;
M:':S#;;DC(>Y<?ZI<<A?OMQ@`'</E/X3?LY?M'?\%%/':_&7XY>(;O3_``L9
M"(;UDVAX@W,%C"<A4!X,AXSDDR,"*"F^Q!\2/C7^TS_P4J^(#?"[X3^'Y]-\
M*P3*SV(F*P1Q[OEN+Z8<,>,B,9`(PBLPW'G?VU?V#]2_94\.^'O%>C>()];T
MV^C%KK%[)`(Q!?\`S,-JC.V-T!"Y)(,;9/S`5^DWPH^$/P\^"7A"#P-\-/#,
M&FZ?!RRQC+S/C!DD<_-(Y[L3[<``4OQ=^%WACXT?#?5_ACXPM]]AJ]H878`%
MHG^\DJY_B1PKCW447%RGXQ>#O%WB#P#XKT[QKX5U![74M*O([JRN$/W)$;(S
MZCC!'0@D'@U^P_[.'QRT#]HGX/Z1\4=#V1M=P^7J5FK9-I=I@2Q'/.`W()ZJ
MRGO7Y#_%GX8>*/@S\1]7^&7C"V\N_P!(O&AE90=LJ]4E3/\`"ZE6!]&'3I7N
M7_!-+]I\?`[XOCP#XIU`Q^&_%LL=O.TC?):7F=L,W/"@D['/'#*Q.$IR)B[,
M_4"BBBI-#&^(7C?1/AIX%U?X@^))BECHVG37ER0>2L:%MJ^K'&`.Y(%?BY\0
M/&VM_$GQQJ_C_P`1S>9?:SJ,MW=')P&D<MM&>BC.`.P`%??7_!7CXW?\(Q\,
M=)^"&D7>+OQ)<B[U-%;E;.!@54^SS;2/^N+"OSMJHD2W/J/_`()3?`__`(6+
M\>I?B7JUF7TSP;;B>,L`5>]EW)".>NT"23(Z,B>M?IC7B/\`P3Z^"'_"C_V:
M=&LM1L_*U;75_M;5M\>UU>908XSW!2((I!Z-NX&37A_[7?QMMM$_X*0?#;2+
MG4_)T[PZ;*&_/F[5C>[F)=GY^Z(V@8@_W<TMQK1'V]1112**^JZ5IFNZ;/HV
MM:=!>6EU$T5S:W,0DCE0C!5E8$,".QKX-_;._P""7]SH$5Y\4/V:[&2XLT#3
M7_A/<6EA7JS6I/,BCD^4?F_NEN%'WU10)I,_"NOT'_X)9?M=:]\0+:?]GCXA
MZA)=WVE6)N?#VHSR;GEMD*J]NY/+%-P*GD[<@X"#/R[^W_X+\->`OVN/&&A>
M$TCCM)+N&[:WB&!#+/!'-(H`X`WNQ`'`#`=JZG_@E=HFJ:G^UYIFH6$4C0:;
MI%]/?.B\+&T1B&3C@;Y$';G\JIZD*]S]1J***DT"BBB@`HHJEKWB/P_X5TYM
M7\3Z[9:;:(0&NK^Z2&-3V!9R!1JP+M<O\;_^2,>+_P#L5K__`-)I*\P^('_!
M2_\`8;^'-_\`V+??M!Z-J^HL_EQ:;X5635YI)/[@%FL@#=L$C&.<8KA?BG^W
M#\5/B=\,/$ME\$OV%/B7J%A+H-Y'<:YXPCM_#UJD)@<-/']I=I95"DG`C!)&
M`.<UTT\/7YDW&R\]/S(=2'<^)OV>[W;\'/#"9Z:+;_\`H`KT6UU2*&(S3S*B
M*,L['``]<FOF?X?W?QB@^$6E:BOBZTTG2K;2HC`FBZ(]]?2QA1C(<[0V.>%(
M%>?ZC\0M5^)FHMH7@CP7XA\6W0;/VCQ/>R3I$<_>%K"5AC`..7W#U%=WU&5>
MM-J2LF[^7WV7XG/[3EBE8^M]:_:J^#7A622S_P"$M&JW<2;GL]"A:\<8]3$"
MJ?\``F%>/>._^"HVJ`FT^%'PYCC[)>Z]*7)_[8Q,`#_VT/TKRSX@_L^?'^Q\
M+VFJ>);"?4(Y[CRXM#\/(ICLW;A6:*%0BY)Q\BD=BRY&<*/X9>`/A?B\^-VO
M-=:B@RG@_0+E&GW<$"YN/F2W'JJ[GP?X:[L-@L`E>_.^V_Y6_'3S,I5*E[;&
MEJWQK_:Q_:?U9_#$7BG6M36529=,TLBVM(X_[TH3:@0=WE.!W-;?P^^$'[,_
M@N&75_C+\29/%^K6LA'_``AG@@.R$@;F::^8+'Y0!P[QL`O)#M@BN6UGXC>+
M/''AEM*26T\&>!H92HTO1XF6.Y<?PX)\R]FP1DR,57()*`BN-UGQ6L]@WA_P
MW9'3]++`R0A]TMT0>'G?`\PCJ%P$7J%!))]*-*4H\D?=79?J_P#+[S+FUN]3
MV.^_;4:/4/\`A"=+^'EIH7P]C:5[CP=X+U!M..H2["J&ZO47SIQP@<C8&`X'
M`-6?%?[2_P`3=>O=!^*7QA\374<6DF&X\`?#[1[R6WBC$>WR9YL,72``8#LQ
MGF`PK*C>:/GM(WE=88D9F9@%51DDGL!7Z$_L#_L(#PO<6_QZ_:%T]K[Q'.5G
MT?1]1S(;#H5GF#9W3]-JG_5]3\_W,,5]4P=/G:_S?]=7O8N'/4=D;/\`P3W_
M`&6/%7[2O[9=W\2OV^=,FUO5K7P7:^(]&T#4V!@CCFNYH88YH,81$,<CB#A0
M7!<$[EK]6&AB>(P-$I0KM*%<@CTQZ5\F_LPS"?\`X*!^*'!SCX-:6/\`RK7U
M?6M?-XVM*M43>BLK+HO0[:45&)^<O[;'_!-KQ?\`#_6K[XF_`;0Y=5\-W$KS
MW.B6<6ZYTK/)"(.980<XVY91P00-U>&?LN_M$^)_V7OBY:_$/1;3[3`4-KK.
MF.VT75JS*73/\+`JK*>S*,@C(/[&UYI\7OV0/V<_CC+)??$'X7V$U_(26U2R
M#6UT6_O-)$5,GT?</:N0OE[$WP0_:L^!G[06EPWGP]\<VKWDB`S:+>2K#>P'
MN&B8Y."<;EW*>Q->BU\A:_\`\$<_@?>71F\.?$OQ/81EB?)N#;SA?8$1H<?7
M-10_\$HM0M4:TM/VL/%$5JS'-NEF0"IZ@XGQT[X_"C0+R/JOQ=X_\#>`-/;5
M?'/C+2]&MD7<9]3OXX%Q]7(S7RY^T5_P5B^&/@B&X\._`C3_`/A*-5`*C5+A
M&BT^!O49P\Y'HNU3U#GI3])_X(_?!(WAOO&'Q0\6ZHY/S;)H(=V,`9)C=CP/
M4=NF.?5?AS^P/^R?\,IDO-'^$-A?72$$76N,U\<CH0LQ9%/NJCFC0/>9^>&F
M?#+]K?\`;D\=S>.5\/ZIKUQ=/MDUF\7R+&V0$XC1VQ&BKSB-,GKP2>?L']F3
M_@EA\-?AA+;^+?C7>0>+-:C`=-/$1&G6S_[K<W!'JX"_[&0#7U;###;0I;V\
M2QQQJ%C1%P%`X``'0#TI]*X**1SOC_XH?#/X/>'_`.W/B'XPTW0["-,1->3K
M'N"C[L:?><X_A4$^U?$7[5'_``5<U7Q):W'@C]FJWN=+MGS'/XHNXPMS(O0_
M9XSGR@>SM\^#P$(S7T/KO_!-O]E'Q/J<NL^(/">K7EU,Q+S7/B2\=CR3C)DX
M'/2JG_#KS]C;_HGU_P#^#^Z_^.4`^9GR%_P3B^"/PW_:)^-VJ:E\:-574I--
M@6^M](OKG+ZK<-(2SR;CNE1,$NO.XN-QQD']/+6UMK&VBLK*VCA@AC5(88D"
MK&H&`H`X``&`!7@4'_!,3]CZUF6XM?`VI12(<J\?B&[5A[@B3BO0_A-^S?\`
M#3X+:Q<:YX(.L^?=6OV>4:EX@NKM`FX-PLSL%.5'(&>U`)-'?445YW\4OV8/
MA9\8?$B^*O&1UW[6MJMOC3O$=W:Q[%+$92*15S\QYQD\>E!1\G?\%C_#7P]7
M5_"OB^QU:S3Q.Z2VE_81R@S2V@&^.5U'("L64$XSOP,[>/B"OU3G_P""8G['
MUU,UQ=>!M2ED<Y9Y/$-VS'W),G--_P"'7G[&W_1/K_\`\']U_P#'*:=B&G<Y
MC]@7]O+PC\4?`]E\+_BUXIM]/\6:5`L$5UJ-PL::M$HPKJ[$`S!0`ZGEL;AG
M+!?H_P`>_$7P1\+_``Q<>,O'WB>TTK3+:,O+=74H4'V4=78]E4$DG`!->+_\
M.O/V-O\`HGU__P"#^Z_^.4^;_@F1^R#<)'%<>!]2D6)=L:OXBNR$'H,R<"D4
MN:Q^>?[6'QYNOVC_`(Y:Q\3#%)#8RNMMHUM,?FALX_EC!]&;F1@,@-(W)%<Y
M\&M/\):M\7/"^F>/K^*UT2XU^T35[B<X1+8S)YA8GH-N<D\`<G@5^EG_``Z\
M_8V_Z)]?_P#@_NO_`(Y1_P`.O/V-O^B?7_\`X/[K_P".4T[$\K9[]9W-I>6L
M=W87$<L$B!H9(G#(RD9!!'!&*_'/]K/QZ?B9^TIXU\9"7?%<>()X;5_[T$)\
MF(_]^XTK]&;#_@G3^SAX>LIH_!=AKND7#HWDS6WB:]"I)CY7*+,`^#@XSSC&
M:K?L\_\`!.?X#_!;0)8?&V@Z9XYUFYE8W.K:_HT;QA"<JL=O(TBQX'5LEB<G
M(&%`AM-GEO[%7_!33PC?^&]/^%G[16KG3M3LXEM[/Q/<G-O>(O"B=NL<@&`9
M#\K8RQ4]?LG1M<T7Q'IL6L^'M8M;^SG7=#=V5PLL<@]5920?PKQCQY_P3F_9
M$\>1LS_"R/2+AAA;K0;N2V*#VC!,1_%#7F'_``Z6TWPS>2WGPC_:8\5^''=C
ML?R%D<#CAFAD@W<9&>.O3U0+F1]@5XE^U!^W7\&_V<=%N[)=<M=<\4!&6T\/
M:?<!W27L;AER(%!QG=\Q'W5/;QC4_P#@EY\=_$4/]F>)?VT-6N[-V_>1W-M=
M3#'KL>ZP3[9_&K_@K_@CA\(]+FCG\>?%77=8V$%HK"UBLD?V.?-;'T8'WHT"
M\CX=DB^*7[27Q:N+G3])NM=\3>)-0DGDM[.(DO(QR2!T1%'<D*JCD@#-?IC^
MPI^Q_#^RKX`N7\0W<%YXIUUD?6+FW.Z.!$SLMXR0"0NXEFXW,?15KT7X0_`#
MX/?`?26TCX4>`K+25D&+BXC4O<3_`/729R9'&>0"V!V`KL:=P4;!1112*/CH
M?M>_\%2OB&V?AA_P37M-!@)^6[\:>-H!@<X+1?N'&1QM`;!/)JW:^%_^"TWQ
M"<3:]\4/@S\/[=SRFB:1=7]Q'P/X9Q)&>>/O]V_V:^NJ*ZOK,5\-.*^3?YMF
M?(^K9\G+_P`$^/VG/'HS\??^"F?Q+U".5/W]KX%L[?P\G(.Y,P[PR\XY4`CM
MV&WX6_X))_L1:-J:>(/&'P_U3QIJBX_XF7C;Q)=W[MT^\A<1-T'5*^EJ*EXO
M$/:5O2R_*P_9P['.?#_X0_"CX46?]G_"_P"&/A_PY"4"-%H>CP6@91V/E*N?
M7FHOC?\`\D8\7_\`8K7_`/Z325U%<O\`&_\`Y(QXO_[%:_\`_2:2LHMRJ)ON
M5:R/QP^"5[L^%_A],]-*AY_X"*Z+Q%\1?!/PSTE];\2ZE;V43N6"(H\RXD_V
M5'+-[_F0*\BMOB'??#SX":7X@TW3OM,\>GP1QJV=D99<!VQSM'ZD@9&<UX5K
MVJ^-/'GB;S-<DO+[4KEE6*%T)?YN55%[#G(`&.:]C#Y>\56G.3M%-_,XY5>2
M*2W/2_C%^V)XY\>K+H7@R2;0]);*LT,F+JX7_:<?<!_NK[@EA7G%KIFE>'%&
MH>+;=KBZ(#6^C[RI.>C3L#E%]$&'8<Y0%6,^H6=MX#D-E;RQW>M1C-S-'AXM
M/;^ZIZ/*.A;[J'A<L`PV/`'PVL;_`$:;XK?%"]FMO#EM,0%5\7&K3\GR8<]<
MD?,_89[@D>W"-##4;05H_B_UU_K0YVY2EJ86K6WBCQ/HTGCC6KB-+.!Q;6:R
M8C5R#GR;>,#&$#;B%`5<C)RZAL2NO\:ZAJ7C+3?^$Z\01)IVG`&R\+Z1;<(B
M(V2B#_GFF[YI#R[MW)8KZS^PS^S9;>.M:C^+/CJP631]/G_XE=I*,K>7"GEV
M!ZQH?P9ACD*P-SQ,,/0<Y].GZ>H*+E*R/3_V`/V.(/#[67QT^*VG!K]U$OA_
M2+B('[,I^[<R`_\`+0]4'\'WC\Q&W[5T[4,8^:N$T[4>GS<UO:=J(8`%N:^0
MQ->IBJO/-_\``.^$%"-D==^R5+YW[?7BIL]/@]I8_P#*K>U]?U\;?L9S>?\`
MMX^*WSG'PBTP?^52]K[)J*^\?1?D7#9GDO[<>N>`O"'[*_C+QW\19KY+'0-%
MGO;?^SM;N=/E>[$;1V\:S6TD;@O+(B`;L$LN1P*^7O\`@C?^SWXI^(_P(M_V
MF/V@?B5XXU_4-5UJ1_"UIJ'C?41;6]K;2!/-,2S!9&>9)01(&4HBX&&;+/\`
M@N?\3/$7BG0OAW^Q)\.I#+KOQ%\2P2W-JCXW0I*L-O&_HKW$@?..ML>1CGL/
M^"GMM\-_V6?^"7W_``J&PMS*MM9:=X;\*Q?:'A>2X"A#,0C`NPA2>4@Y!<`D
M'K7;1A..%A33LZDON2T_/\#*33J-]$CZSO?B3\.].T>X\0W_`(^T2"PM+DV]
MU?3:K"L,,P`)C=RVU7`(.TG.#TJUJ'BWPMI/AF7QIJGB6PM]'AM3<S:I/>(M
MLD.,^89"=H3'.[.*_.3XV?L2?`#]D7_@E%<Z]\;?#ESK?C1/#J)IO]K:E*1I
M6L7Y7,=I#D1Q^4[L[';O<0'<Q`4+L?%F^?\`9%_X(4:!X`\?V=M>Z]XCT..P
MTRRU*W64PW&I3RWF`KJ=LEO;R2%2!E'A7!&`:S^ITY6Y)-WER[?BM2O:-;KI
M<^K/V7_VS_`G[6GBGQ=-\+A%)X5\/:A%IFDZW/+LDUJ\"-)<M#$V&$,:-!M8
MC+EW.%"C/J'BKXA>`O`Q@'C7QOH^C_:GVVPU74XK?SFSC"^8PW'V%?$E_I'A
M7_@E_P#L(_#VS\)?"C0;WXU^(4M]&\/W=UI<#78UJ_#/,7F($ABA\UHP,X.(
MD.`Q(9XH_8Z^.OB[]FSQ!\+?%7[&'AOQ!X\\2:1(NJ?$[Q+X\M;S4)-2=>+I
M6>VWPQH_,<,;JJ*`H[DDL-1E/F4K0O9;:VW>KV!3DE:VI]Z12Q3Q+/!(KHZA
MD=&R&!Z$'N*QKKXD_#NR@BNKSQ]HL,<U_P#889)=5A59+K('D`EN9,D?(/FY
M'%?G-^U=X+\<_LE_\$=?"_P&^-^IW5WX^NM<;2M!M=-URX=8`]Y-,%'DN!<(
MMHNQ5<%4,RJ!P`?9?A5_P1[_`&6O"OP/\"Q?'E=6U/6/!L*ZGJE[<Z](EJDA
M_?W%MY0/EK:B3<3M"NV,LYR:EX:C"'-*>EVE9;VZ[C]I)NR1]A3^(=!M=8C\
M.W.N6<>H30--#8R7*":2)>&=4)W%1W(&!5?PQXY\$^-4N&\&^,-*U86<GEW9
MTS4([CR'Y^5]C':>#P?2OSA_X)@_LB?"S]K?QW\5OVN?'^AZH?"FO^*;O2_#
M7AXZK/%!=V/F"9ENB'\VX0`VR[&?RV:-]RMM4+U7_!&GX?\`A#4_VA_CU\=_
MA#HR:3X!F\1_V%X4T^UD9H9(XY7F+C).,1F!@,G`N"!@`9JK@Z=.,_>=XVZ:
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M7U[Q8M\HMWU"64)!9VH_Y;Y5)V:4':#&%7=N)#_VR?V4_`G[6UUX,\%>.?C+
MK'AV#2=;;4ET/1M32!]:*!6VD$[LH$8AU!*;F/'!'C__``2/_8W^'/P[_8X\
M.?$CXC_#[2+CQ/XHFD\1'5[_`$^(W5A!*!]E\F<J)(0(4CF!4J5:5B"#S7DO
M_!-(_#RX^,?[0'_!27Q"]['X-T"6^T_PQ=ZA=SW<OV*,FXF<27+L[2^3';`9
M8DF=UR`<'5T80JSE1;7)HNMWM^/H3S-Q2DMS](-7UK1_#VGR:QK^K6UC:0_Z
MVZO)UBC0$X&68@#GBJGA+QSX)\>V#:MX%\8:7K5HK!3=:3J$=S&#C.-T;$9Q
MS7QU^PEX9U7_`(*#ZAJ/[<_[4FBQZGI,VJW%E\+O`M\?/TO2+.%BCW1A8;)K
MEI`T9E89S$Q``V!.%T_3+'P!_P`%[+'P;^S]91:-I=YX0:7XAZ7I,(BM78V$
M\H,D284$L;)@0/OL&.<MG'ZI'FG!R]Z*;?;3I_74KVCLG;1GZ$ZAKNB:3=6M
MCJNLVMM/?3>590W%RJ/<28R4C!.7;&3@9.*JZ5XW\%ZYK5UX:T3Q?IEYJ-B,
MWNGVNH1R3VXSC+HK%DYXY`YK\Y_@9\!O!'[;W_!53XK_`!8C?5[/P9\/9FTQ
M)=)UJ>&34;]P]O,IG#>8(I-EZ6$3+\C1KD*WS:7[)OP;^%\__!9CQM>?LY^$
M+?P]X0^&'AI[#58M.W^3=:C*@@>,@L=IWM-QT)M,XR<U;P5.*DG)W4>9Z=^F
M_F)5&[:=;'Z'ZYK^A>&--DUGQ)K5IIUG%CS;N^N5AB3/`RS$`5!X4\:>#O'>
MF?VYX'\6:;K-D7VB\TJ_CN(MV`<;XR1G!'&>]?)?Q`\-?#V7]NOQ#\7/C5\4
MX_B;'H.ABV\'?"+0=!.H_P#".,8T,MW=Y/V>TD.V7$MRT8(F^^`B+7-_\$:8
MD^)'BKXX?M8^']`/A_PKXV\:K;^'-!BB2"*&&W$DA=HT)0/MN8E)7Y=PE`)[
M9O"Q5!U+[)=.KZ?\'8?M'SVL8W_!4B#Q%\9OVR?A'^QU\-OB-XKLKKQA-]K\
M9V&F^)+F*TCTH/C=]G1A$7$4%Y(21GY%[-7W]I]A9:580Z5IMJD%O;0K%;P1
MKA8T4`*H'8``"O@S_@FY$?VL_P!NCXR_M[ZDOVC2;*^_X1CP-*V&00J%#2)Q
M\K"WC@)QU^UOUSFOOFGC/W:A1_E6OJ]7^B"EK>7<*^/O^"U7COP]\+OV1I/&
M$6O:UIWBNXU.'3/"-SH_B.\L6BFE=99I&2WE190(()/]8&`)4<;N?L&OS4_X
M*`,W[;O_``50^&?[%UDQN/#O@W9>^*8E^Z3(JW=TK'D<VL4$:DCAY6'?%&`@
MI8E2>T=7Z(*SM"W<^C?^"='[,T_PN_9^\)?%[XS^.?%6L>-M1T8:KJM[XA\8
MW\T%DEQ&S+#]GDF\E?+AD"L64G>&.[A=OT#??$[X:Z98V&IZE\0=#M[;56"Z
M7<3ZM"B7A/01,6Q(?]W-?$G_``7#M;3XF:?\)_V7_"-HLOB_QQXP6'3V6:3%
MO9KMC<O&K!=IEEA;<P.!`^.A(\I_X*@_LK_`WX/_``(\(_!?P-\*-:NOB)J?
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MD[\J/J:BH;&U-C9PV?VB6;R8E3SIWW.^!C<Q[D]2?6IJY30****`"BBB@`KG
M/B]IU]J_PG\3Z3I=I)<7-UX=O8;:")2S22-`X50!U))``]ZZ.BFG9W`_$OP7
M^S=^U9H?A&P\/ZK^R+\29'M[-(I@/"<K*2!@]>HK4L_V=/CY:^(G\6_\,7?$
MC^TGB$;7G_"'R%]H&,9SZ<9ZX&.U?M!172\1%R;Y=_-]3+V6FY^-&B_LX_%[
M1;K4+RT_8=^(J2:J3_:+#P5(1,#U!!.,'J5'!/)&>:U]3^"GQAU_PX?".O\`
M[$_Q+N--,:H+,^"Y`B`#"[<,-A'8K@CMBOV`HH>(BW>VOJP]GYGY&3?!SXE:
MAX<A\(ZM^PQ\1Y]-@B$4-E)X%9DC4#'R@GY3[CGOFN@\,>%_C%X3T:U\/:)^
MQK\5K:RLX5BMH(O!DF(T48`Y?GZGD]2<U^J=%)UX-6<?Q8>SMU/S(M+KXWPX
MW_LA_%SCT\%O_P#%UIVGB'XRP8W_`+(/Q>X]/!3_`/Q=?I)14^UH_P`GXC]F
M^Y\8_L!^'_B=J/[5GBOXD^+/@OXO\+:7+\/+'3+:;Q3HC6GGW$=]<2LJ9)#8
M653USUKZV\<^+O\`A!O#DWB(^&-7U@Q,JBPT.R^T7,FXXRJ9&0.I.1@5L45-
M2HJDT[::?@5&/*K'YN>$O"'[1OQ3_P""K4/[7WQQ_91\?67A+2+1[/P=:G38
M)GM-D+10-,HEPH+2SSG!;9(XY(&X=K^V1X?^,'[47[:WPET[4?V=O'!^$_@'
M6CJ.MZF^B\:A>[@RD0[][P`Q1)N(#8EF(4C!/W=172\:^=245HK+?3_@D>RT
MM?K<^#/^"D7A[XU?M6_&[X;_``@T_P#9Y\<77PL\,^+8]1\;ZM%I(*Z@5D$9
M$,1?<Z+#YP#E<GSSM4[?FL_\%1_`/QM\?_M2_`R31_@#XH\;?#WPOJO]J:W9
M^&+19A/="=#Y4H8K&@$<*@&1E4B5UW#)K[JHJ88QTW"T5[J:^_KZ@Z:=]=SX
M!_X*K?![]L?XLZ1\'?VC/AE\&IKC7/`&OWFH7OA#3;M=0FM&:>UEM9&$04SM
MBV`E6(N$9L(S+ESZY\./CQ^W-^U'HD>C_P##+][\%M+GB_XG7BKQ#JRW.HQQ
MX^>/3[%H$;SST66<!$SNV2$!#]144GBKT8P<%[M[/72[OWU^=Q^SM)N^Y^>G
MQ]\%_&?X]_MW?"#4-8_9V^(S?"#X5F-X]1U33WNKJ_O$42"XE620RR*TD-HC
M-)ND(61R#O(KWO\`X*:^*OC=<_LV^(?@W^SS\(_$OB3Q)XMTW[`UUI-B#;65
MG,Q2X+RLP&]H@Z!5RP\P,<#!/TA10\5>4'RKW-E\[Z_J'L]&K[GQ99V/Q9_9
MR_X)>Z-\!?V?_P!G[QK>>.+[P=)8&WCTD1-I^H7);[9=2NSX4K)+,\8!;=B/
M`V\CRSQU\#/VIOA#_P`$=O#OP5_9U^%WBJU\57^LD?$;3[2P9=3>"83R7`C2
M,EI$+_9H=T>2T2$$8+8_2:BJCC91=^5?%S/S8G23Z]+'YI?M2Z;^V/XR_P""
M=7AG]G7X(?L.ZWX2T&:33M+U735E6XU2>.-?->3[+`O[F)KB-6>:9P[ECN0!
MF:NF_P""EOP=_:$\8_L.?"?X,?"C]G'7TTK3]5M4\0^%-$G2^OK*TM8#%:Q2
MFW!5BRDL[*61)%7YFX:OT'HJHXZ491:BM&WUW?S$Z5T]3Y-_:E^+G[1^H_LD
M>(/AM\'?V1O%NG>(?$.C?V7X:TRS6&4Z5ITL2Q/)=21MY4$RIYP2**24K^Z+
M%"65<3X0_L<>)=;_`."15U^R?H?A^_\`#/BS4O#\WV^#7+<V[R:LTPN65V&<
MQ,P6$2#(V#H=I%?9M%9+%.,%&*2L^;YHKV:;NWTL?%_["GQ0^-O[/7[(.A?L
M\ZQ^QO\`$*X\>>%Q<VD6F'3$M]-O6ENII4F_M)V^SI'B0;SEG!#$*P()E\*?
M`#XK?L?^`_B%^T==>$-1^(OQ]^)L-V[S^%].,MII4K#,%I&TK*4M8G\LLS8:
M00H`OR+7V711+%-SDU%+F=WY];>EP]GHM=CX?_X)]^%_B1^Q5^P->P2_L[>-
M-1^)&HZOJ%[?Z"-)!DN;YLI;YE+;1;^5'`6<MD,TF`6R*X3]EOX%?M;_``/_
M`."<?QDU;PQ\.O$EC\</%VLO=W!N+18KN>)Y(T9K=P</(D3WDJE<,)),*,[<
M_HW15O&R;DW%>\TW\NGH+V2LE?8_-'P)%^V;X*_X)7ZW\&/A7^Q%XCT/6Y]*
MG@\1:MJ<W_$SU>6\N2ES/!9JAN9IC#)RTFS8JX7?L`KO/"#?M#_`W_@EW:?L
MZ_"W]DOQK:^.+_PI)8VL,<$4GDRW9;[7>SR(X$#!I)S'$2TH"P[U3)"_>5%.
M6-YMX+XN;KO]X*E;KTL?&/[.UI\9?V*/^"6UI#\(?V==9U7X@Z1NDU'PWJ]D
MT;R7T\X::=E1@TT,<;@`QG++$!E<,1[=^P=\>/B5^TQ^RSX8^-OQ8\(66BZS
MKB7$CVFG1R)`\27$D<<T:R.[JKH@898Y!R"016!^U_=7?B7XR_"/X&:Q>SOX
M4\9:EJJ>*='BG:)-3CM[>-XX960AVBW,VZ+=LD!VNK+Q7O=K:VMC:QV-C;1P
MPPQA(88D"JB@8"@#@`#@`5%>:G3YFO>DV[^6UOO'!6=KZ(Y;XM_%*[^%FBQZ
MG8?##Q1XIGF63R;#POIJSR;E`(#EW14#$X!)]?2OA/\`X)B?#'X_?#G]J?XH
M?M(?M4_LZ^,M-\0>-$EDTR_ATH7$%NDLTMU=1'8^Y3F*V2,*ISC:,<`_HS14
M4L1[*E*"7Q;OJ.4.:2=]CX3\`>$_C%\9O^"K<O[3WQD_9\\9:)X/\,>%9M-^
M'LVHZ2&"S*I!EE5'8IO$UXZC!.7B!PP%)J?A#XT_M'_\%5O!_P`9_B)^S_XR
MTGX<>!=*DM_"UQJ>F*J2WY5F^TS(')B4R29!ZXMXL@$D#[MHK3ZX[W4?L\J\
ME_F+V:MOUN?FYX\\'?ML?L:?\%/O&/[37PW_`&9=6^)?A?Q_;FU_XE+%F$#K
M;N5,B!S;/%)`%'F+L9!@$9!7[`^"TG[4WQ2\06OQ0^//ANW^'VE6*2G2?AYI
M6LK?7,\K*4$^H7:!8W`4L4MHQM#,'=F9%">QT5-7%.K%)Q5TK7UO9?.WX!&G
MRO<\(_8@^./[6/QWM/%WB;]I7]GR+X>Z?;ZRL'@[3YHYH[V:W&_S#<+*QW;?
>W0$JJBOE\+A<GW?(]1116%249S<DK+LBXII6N?_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
